1
|
Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD. Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer. J Clin Oncol 2023; 41:3278-3286. [PMID: 37315390 DOI: 10.1200/jco.22.02758] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/16/2023] Open
Abstract
PURPOSE Panitumumab, a fully human antibody against the epidermal growth factor receptor (EGFR), has activity in a subset of patients with metastatic colorectal cancer (mCRC). Although activating mutations in KRAS, a small G-protein downstream of EGFR, correlate with poor response to anti-EGFR antibodies in mCRC, their role as a selection marker has not been established in randomized trials. PATIENTS AND METHODS KRAS mutations were detected using polymerase chain reaction on DNA from tumor sections collected in a phase III mCRC trial comparing panitumumab monotherapy to best supportive care (BSC). We tested whether the effect of panitumumab on progression-free survival (PFS) differed by KRAS status. RESULTS KRAS status was ascertained in 427 (92%) of 463 patients (208 panitumumab, 219 BSC). KRAS mutations were found in 43% of patients. The treatment effect on PFS in the wild-type (WT) KRAS group (hazard ratio [HR], 0.45; 95% CI: 0.34 to 0.59) was significantly greater (P < .0001) than in the mutant group (HR, 0.99; 95% CI, 0.73 to 1.36). Median PFS in the WT KRAS group was 12.3 weeks for panitumumab and 7.3 weeks for BSC. Response rates to panitumumab were 17% and 0%, for the WT and mutant groups, respectively. WT KRAS patients had longer overall survival (HR, 0.67; 95% CI, 0.55 to 0.82; treatment arms combined). Consistent with longer exposure, more grade III treatment-related toxicities occurred in the WT KRAS group. No significant differences in toxicity were observed between the WT KRAS group and the overall population. CONCLUSION Panitumumab monotherapy efficacy in mCRC is confined to patients with WT KRAS tumors. KRAS status should be considered in selecting patients with mCRC as candidates for panitumumab monotherapy.
Collapse
Affiliation(s)
- Rafael G Amado
- From Amgen Inc, Thousand Oaks, CA; Ghent University Hospital, Ghent, Belgium; University Hospital Gasthuisberg, Leuven, Belgium; and the Ospedale Niguarda Ca' Granda, Milan, Italy
| | - Michael Wolf
- From Amgen Inc, Thousand Oaks, CA; Ghent University Hospital, Ghent, Belgium; University Hospital Gasthuisberg, Leuven, Belgium; and the Ospedale Niguarda Ca' Granda, Milan, Italy
| | - Marc Peeters
- From Amgen Inc, Thousand Oaks, CA; Ghent University Hospital, Ghent, Belgium; University Hospital Gasthuisberg, Leuven, Belgium; and the Ospedale Niguarda Ca' Granda, Milan, Italy
| | - Eric Van Cutsem
- From Amgen Inc, Thousand Oaks, CA; Ghent University Hospital, Ghent, Belgium; University Hospital Gasthuisberg, Leuven, Belgium; and the Ospedale Niguarda Ca' Granda, Milan, Italy
| | - Salvatore Siena
- From Amgen Inc, Thousand Oaks, CA; Ghent University Hospital, Ghent, Belgium; University Hospital Gasthuisberg, Leuven, Belgium; and the Ospedale Niguarda Ca' Granda, Milan, Italy
| | - Daniel J Freeman
- From Amgen Inc, Thousand Oaks, CA; Ghent University Hospital, Ghent, Belgium; University Hospital Gasthuisberg, Leuven, Belgium; and the Ospedale Niguarda Ca' Granda, Milan, Italy
| | - Todd Juan
- From Amgen Inc, Thousand Oaks, CA; Ghent University Hospital, Ghent, Belgium; University Hospital Gasthuisberg, Leuven, Belgium; and the Ospedale Niguarda Ca' Granda, Milan, Italy
| | - Robert Sikorski
- From Amgen Inc, Thousand Oaks, CA; Ghent University Hospital, Ghent, Belgium; University Hospital Gasthuisberg, Leuven, Belgium; and the Ospedale Niguarda Ca' Granda, Milan, Italy
| | - Sid Suggs
- From Amgen Inc, Thousand Oaks, CA; Ghent University Hospital, Ghent, Belgium; University Hospital Gasthuisberg, Leuven, Belgium; and the Ospedale Niguarda Ca' Granda, Milan, Italy
| | - Robert Radinsky
- From Amgen Inc, Thousand Oaks, CA; Ghent University Hospital, Ghent, Belgium; University Hospital Gasthuisberg, Leuven, Belgium; and the Ospedale Niguarda Ca' Granda, Milan, Italy
| | - Scott D Patterson
- From Amgen Inc, Thousand Oaks, CA; Ghent University Hospital, Ghent, Belgium; University Hospital Gasthuisberg, Leuven, Belgium; and the Ospedale Niguarda Ca' Granda, Milan, Italy
| | - David D Chang
- From Amgen Inc, Thousand Oaks, CA; Ghent University Hospital, Ghent, Belgium; University Hospital Gasthuisberg, Leuven, Belgium; and the Ospedale Niguarda Ca' Granda, Milan, Italy
| |
Collapse
|
2
|
Moody G, Belmontes B, Masterman S, Wang W, King C, Murawsky C, Tsuruda T, Liu S, Radinsky R, Beltran PJ. Antibody-mediated neutralization of autocrine Gas6 inhibits the growth of pancreatic ductal adenocarcinoma tumors in vivo. Int J Cancer 2016; 139:1340-9. [PMID: 27170265 DOI: 10.1002/ijc.30180] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2016] [Revised: 04/06/2016] [Accepted: 04/15/2016] [Indexed: 02/02/2023]
Abstract
Gas6 and its receptors Axl, Mer and Tyro-3 (TAM) are highly expressed in human malignancy suggesting that signaling through this axis may be tumor-promoting. In pancreatic ductal adenocarcinoma (PDAC), Gas6 and the TAM receptor Axl are frequently co-expressed and their co-expression correlates with poor survival. A strategy was devised to generate fully human neutralizing antibodies against Gas6 using XenoMouse® technology. Hybridoma supernatants were selected based on their ability to inhibit Gas6 binding to the receptor Axl and block Gas6-induced Axl phosphorylation in human cells. Two purified antibodies isolated from the screened hybridomas, GMAB1 and GMAB2, displayed optimal cellular potency which was comparable to that of the soluble extracellular domain of the receptor Axl (Axl-Fc). In vivo characterization of GMAB1 was conducted using a pharmacodynamic assay that measured inhibition of Gas6-induced Akt activation in the mouse spleen. Treatment of mice with a single dose (100-1000 µg) of GMAB1 led to greater than 90% inhibition of Gas6-induced phosphorylated Akt (pAkt) for up to 72 hr. Based on the target coverage observed in the PD assay, the efficacy of GMAB1 was tested against human pancreatic adenocarcinoma xenografts. At doses of 50 µg and 150 µg, twice weekly, GMAB1 was able to inhibit 55% and 76% of tumor growth, respectively (p < 0.001 for both treatments vs. control Ig). When combined with gemcitabine, GMAB1 significantly inhibited tumor growth compared to either agent alone (p < 0.001). Together, the data suggest that Gas6 neutralization may be important as a potential strategy for the treatment of PDAC.
Collapse
Affiliation(s)
- Gordon Moody
- Oncology Research Therapeutic Area, Thousand Oaks, CA
| | | | | | - Wei Wang
- Therapeutic Discovery, Amgen Inc., Thousand Oaks, CA
| | - Chadwick King
- Therapeutic Discovery, Amgen Inc., Thousand Oaks, CA
| | | | - Trace Tsuruda
- Therapeutic Discovery, Amgen Inc., Thousand Oaks, CA
| | - Shuying Liu
- Therapeutic Discovery, Amgen Inc., Thousand Oaks, CA
| | | | | |
Collapse
|
3
|
Hughes PE, Rex K, Caenepeel S, Yang Y, Zhang Y, Broome MA, Kha HT, Burgess TL, Amore B, Kaplan-Lefko PJ, Moriguchi J, Werner J, Damore MA, Baker D, Choquette DM, Harmange JC, Radinsky R, Kendall R, Dussault I, Coxon A. In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models. Mol Cancer Ther 2016; 15:1568-79. [PMID: 27196782 DOI: 10.1158/1535-7163.mct-15-0871] [Citation(s) in RCA: 44] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2015] [Accepted: 04/01/2016] [Indexed: 11/16/2022]
Abstract
The MET receptor tyrosine kinase is involved in cell growth, survival, and invasion. Clinical studies with small molecule MET inhibitors have shown the role of biomarkers in identifying patients most likely to benefit from MET-targeted therapy. AMG 337 is an oral, small molecule, ATP-competitive, highly selective inhibitor of the MET receptor. Herein, we describe AMG 337 preclinical activity and mechanism of action in MET-dependent tumor models. These studies suggest MET is the only therapeutic target for AMG 337. In an unbiased tumor cell line proliferation screen (260 cell lines), a closely related analogue of AMG 337, Compound 5, exhibited activity in 2 of 260 cell lines; both were MET-amplified. Additional studies examining the effects of AMG 337 on the proliferation of a limited panel of cell lines with varying MET copy numbers revealed that high-level focal MET amplification (>12 copies) was required to confer MET oncogene addiction and AMG 337 sensitivity. One MET-amplified cell line, H1573 (>12 copies), was AMG 337 insensitive, possibly because of a downstream G12A KRAS mutation. Mechanism-of-action studies in sensitive MET-amplified cell lines demonstrated that AMG 337 inhibited MET and adaptor protein Gab-1 phosphorylation, subsequently blocking the downstream PI3K and MAPK pathways. AMG 337 exhibited potency in pharmacodynamic assays evaluating MET signaling in tumor xenograft models; >90% inhibition of Gab-1 phosphorylation was observed at 0.75 mg/kg. These findings describe the preclinical activity and mechanism of action of AMG 337 in MET-dependent tumor models and indicate its potential as a novel therapeutic for the treatment of MET-dependent tumors. Mol Cancer Ther; 15(7); 1568-79. ©2016 AACR.
Collapse
Affiliation(s)
| | - Karen Rex
- Amgen Inc., Thousand Oaks, California
| | | | | | | | | | - Hue T Kha
- Amgen Inc., Thousand Oaks, California
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Wurz RP, Pettus LH, Ashton K, Brown J, Chen JJ, Herberich B, Hong FT, Hu-Harrington E, Nguyen T, St. Jean DJ, Tadesse S, Bauer D, Kubryk M, Zhan J, Cooke K, Mitchell P, Andrews KL, Hsieh F, Hickman D, Kalyanaraman N, Wu T, Reid DL, Lobenhofer EK, Andrews DA, Everds N, Guzman R, Parsons AT, Hedley SJ, Tedrow J, Thiel OR, Potter M, Radinsky R, Beltran PJ, Tasker AS. Oxopyrido[2,3-d]pyrimidines as Covalent L858R/T790M Mutant Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors. ACS Med Chem Lett 2015; 6:987-92. [PMID: 26396685 DOI: 10.1021/acsmedchemlett.5b00193] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2015] [Accepted: 07/27/2015] [Indexed: 01/26/2023] Open
Abstract
In nonsmall cell lung cancer (NSCLC), the threonine(790)-methionine(790) (T790M) point mutation of EGFR kinase is one of the leading causes of acquired resistance to the first generation tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib. Herein, we describe the optimization of a series of 7-oxopyrido[2,3-d]pyrimidinyl-derived irreversible inhibitors of EGFR kinase. This led to the discovery of compound 24 which potently inhibits gefitinib-resistant EGFR(L858R,T790M) with 100-fold selectivity over wild-type EGFR. Compound 24 displays strong antiproliferative activity against the H1975 nonsmall cell lung cancer cell line, the first line mutant HCC827 cell line, and promising antitumor activity in an EGFR(L858R,T790M) driven H1975 xenograft model sparing the side effects associated with the inhibition of wild-type EGFR.
Collapse
Affiliation(s)
- Ryan P. Wurz
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Liping H. Pettus
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Kate Ashton
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - James Brown
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Jian Jeffrey Chen
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Brad Herberich
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Fang-Tsao Hong
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Essa Hu-Harrington
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Tom Nguyen
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - David J. St. Jean
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Seifu Tadesse
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - David Bauer
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Michele Kubryk
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Jinghui Zhan
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Keegan Cooke
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Petia Mitchell
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Kristin L. Andrews
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Faye Hsieh
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Dean Hickman
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Nataraj Kalyanaraman
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Tian Wu
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Darren L. Reid
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Edward K. Lobenhofer
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Dina A. Andrews
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Nancy Everds
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Roberto Guzman
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Andrew T. Parsons
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Simon J. Hedley
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Jason Tedrow
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Oliver R. Thiel
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Matthew Potter
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Robert Radinsky
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Pedro J. Beltran
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Andrew S. Tasker
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| |
Collapse
|
5
|
Beltran PJ, Zhan J, Mitchell P, Wurz RP, Pettus L, Wu T, Chaves M, Reid DL, Radinsky R, Cooke K, Tasker A. Abstract 2587: A novel covalent inhibitor of mutant but not wild-type (WT) epidermal growth factor receptor (EGFR) has activity in vitro and in vivo in non-small cell lung cancer (NSCLC) models. Cancer Res 2015. [DOI: 10.1158/1538-7445.am2015-2587] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Mutations in the EGFR kinase are common in NSCLC. Patients with first-line EGFR mutations (exon 19 deletions, L858R mutations, exon 20 variants, codon 719 variants) initially respond to the reversible EGFR inhibitors erlotinib and gefitinib, but then relapse as additional mutations emerge. EGFR T790M is the most common of these mutations and is found in > 50% of refractory tumors. We assessed the in vitro and in vivo activity of CPD 24, a newly developed, covalent, small-molecule inhibitor of both first-line and T790M mutant EGFR, but not WT EGFR. Inhibition of WT EGFR in normal tissues can be a source of dose-limiting toxicities.
Methods: The effects of CPD 24 were evaluated on H1975 (EGFR T790M/L858R), HCC827 (EGFR exon 19 deletion), and A431 (WT) cell lines. Inhibition of EGFR phosphorylation was measured in serum-starved cells using an MSD assay. Viability was assessed by measuring ATP in cells using a CellTiter-Glo® assay. Dose- and time-dependent pharmacodynamic effects were evaluated by treating mice bearing matrigel plugs containing H1975 cells. Drug levels were measured in plasma samples by LC-MS. CPD 24 was administered to athymic nude mice bearing H1975, HCC827, or A431 xenografts (3, 10, and 30 mg/kg, QD, PO) and tumor growth was measured twice per week with digital calipers. CPD 24 was also formulated in PLGA microspheres and administered subcutaneously (SC) as a sustained release formulation to mice bearing H1975 or A431 xenografts (30 and 100 mg/kg, Q3D, SC). Proliferation of H1975 and HCC827 cells in the presence of CPD 24, growth factors, and a MET inhibitor was measured with an IncuCyte live-cell imaging system.
Results: The IC50 of CPD 24 for p-EGFR inhibition was 4 nM on L858R/T790M mutant EGFR (H1975 cells), 17 nM on the exon 19 deletion EGFR (HCC827 cells), and 510 nM on WT EGFR (A431 cells). CPD 24 inhibited the growth of tumor cells in vitro and led to both dose- and time-dependent p-EGFR inhibition in vivo. Phosphorylation of EGFR in H1975 cells growing in matrigel plugs was inhibited by > 75% for 12 hours by a single 30 mg/kg dose. Tumor growth inhibition (TGI) was observed in two EGFR mutant NSCLC xenograft models (H1975, 89% TGI; HCC827, 139% TGI) but not in a WT EGFR model (A431). CPD 24 formulated in PLGA microspheres achieved drug levels above the IC50 for 72 hours after a single SC dose. Tumor regression was observed with this formulation in H1975 xenografts but not in WT tumors. HGF was able to confer resistance to CPD 24 inhibition in both H1975 and HCC827 cells in vitro. This resistance was prevented by the addition of a selective MET inhibitor.
Conclusion: CPD 24 is a covalent inhibitor of both first-line and T790M mutant EGFR while maintaining > 100-fold selectivity over WT EGFR. The antiproliferative effects of CPD 24 can be reversed by HGF, and this resistance can be prevented by treatment with a MET inhibitor.
Citation Format: Pedro J. Beltran, Jinghui Zhan, Petia Mitchell, Ryan P. Wurz, Liping Pettus, Tian Wu, Mary Chaves, Darren L. Reid, Robert Radinsky, Keegan Cooke, Andrew Tasker. A novel covalent inhibitor of mutant but not wild-type (WT) epidermal growth factor receptor (EGFR) has activity in vitro and in vivo in non-small cell lung cancer (NSCLC) models. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2587. doi:10.1158/1538-7445.AM2015-2587
Collapse
Affiliation(s)
| | | | | | | | | | - Tian Wu
- Amgen Inc., Thousand Oaks, CA
| | | | | | | | | | | |
Collapse
|
6
|
Geuns-Meyer S, Cee VJ, Deak HL, Du B, Hodous BL, Nguyen HN, Olivieri PR, Schenkel LB, Vaida KR, Andrews P, Bak A, Be X, Beltran PJ, Bush TL, Chaves MK, Chung G, Dai Y, Eden P, Hanestad K, Huang L, Lin MHJ, Tang J, Ziegler B, Radinsky R, Kendall R, Patel VF, Payton M. Discovery of N-(4-(3-(2-aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine (AMG 900), a highly selective, orally bioavailable inhibitor of aurora kinases with activity against multidrug-resistant cancer cell lines. J Med Chem 2015; 58:5189-207. [PMID: 25970324 DOI: 10.1021/acs.jmedchem.5b00183] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Efforts to improve upon the physical properties and metabolic stability of Aurora kinase inhibitor 14a revealed that potency against multidrug-resistant cell lines was compromised by increased polarity. Despite its high in vitro metabolic intrinsic clearance, 23r (AMG 900) showed acceptable pharmacokinetic properties and robust pharmacodynamic activity. Projecting from in vitro data to in vivo target coverage was not practical due to disjunctions between enzyme and cell data, complex and apparently contradictory indicators of binding kinetics, and unmeasurable free fraction in plasma. In contrast, it was straightforward to relate pharmacokinetics to pharmacodynamics and efficacy by following the time above a threshold concentration. On the basis of its oral route of administration, a selectivity profile that favors Aurora-driven pharmacology and its activity against multidrug-resistant cell lines, 23r was identified as a potential best-in-class Aurora kinase inhibitor. In phase 1 dose expansion studies with G-CSF support, 23r has shown promising single agent activity.
Collapse
Affiliation(s)
- Stephanie Geuns-Meyer
- †Departments of Medicinal Chemistry, ‡Pharmaceutical Research and Development, §Pharmacokinetics and Drug Metabolism, ∥Molecular Structure, and ⊥Oncology Research, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States, and Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Victor J Cee
- †Departments of Medicinal Chemistry, ‡Pharmaceutical Research and Development, §Pharmacokinetics and Drug Metabolism, ∥Molecular Structure, and ⊥Oncology Research, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States, and Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Holly L Deak
- †Departments of Medicinal Chemistry, ‡Pharmaceutical Research and Development, §Pharmacokinetics and Drug Metabolism, ∥Molecular Structure, and ⊥Oncology Research, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States, and Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Bingfan Du
- †Departments of Medicinal Chemistry, ‡Pharmaceutical Research and Development, §Pharmacokinetics and Drug Metabolism, ∥Molecular Structure, and ⊥Oncology Research, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States, and Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Brian L Hodous
- †Departments of Medicinal Chemistry, ‡Pharmaceutical Research and Development, §Pharmacokinetics and Drug Metabolism, ∥Molecular Structure, and ⊥Oncology Research, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States, and Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Hanh Nho Nguyen
- †Departments of Medicinal Chemistry, ‡Pharmaceutical Research and Development, §Pharmacokinetics and Drug Metabolism, ∥Molecular Structure, and ⊥Oncology Research, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States, and Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Philip R Olivieri
- †Departments of Medicinal Chemistry, ‡Pharmaceutical Research and Development, §Pharmacokinetics and Drug Metabolism, ∥Molecular Structure, and ⊥Oncology Research, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States, and Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Laurie B Schenkel
- †Departments of Medicinal Chemistry, ‡Pharmaceutical Research and Development, §Pharmacokinetics and Drug Metabolism, ∥Molecular Structure, and ⊥Oncology Research, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States, and Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Karina R Vaida
- †Departments of Medicinal Chemistry, ‡Pharmaceutical Research and Development, §Pharmacokinetics and Drug Metabolism, ∥Molecular Structure, and ⊥Oncology Research, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States, and Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Paul Andrews
- †Departments of Medicinal Chemistry, ‡Pharmaceutical Research and Development, §Pharmacokinetics and Drug Metabolism, ∥Molecular Structure, and ⊥Oncology Research, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States, and Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Annette Bak
- †Departments of Medicinal Chemistry, ‡Pharmaceutical Research and Development, §Pharmacokinetics and Drug Metabolism, ∥Molecular Structure, and ⊥Oncology Research, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States, and Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Xuhai Be
- †Departments of Medicinal Chemistry, ‡Pharmaceutical Research and Development, §Pharmacokinetics and Drug Metabolism, ∥Molecular Structure, and ⊥Oncology Research, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States, and Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Pedro J Beltran
- †Departments of Medicinal Chemistry, ‡Pharmaceutical Research and Development, §Pharmacokinetics and Drug Metabolism, ∥Molecular Structure, and ⊥Oncology Research, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States, and Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Tammy L Bush
- †Departments of Medicinal Chemistry, ‡Pharmaceutical Research and Development, §Pharmacokinetics and Drug Metabolism, ∥Molecular Structure, and ⊥Oncology Research, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States, and Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Mary K Chaves
- †Departments of Medicinal Chemistry, ‡Pharmaceutical Research and Development, §Pharmacokinetics and Drug Metabolism, ∥Molecular Structure, and ⊥Oncology Research, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States, and Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Grace Chung
- †Departments of Medicinal Chemistry, ‡Pharmaceutical Research and Development, §Pharmacokinetics and Drug Metabolism, ∥Molecular Structure, and ⊥Oncology Research, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States, and Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Yang Dai
- †Departments of Medicinal Chemistry, ‡Pharmaceutical Research and Development, §Pharmacokinetics and Drug Metabolism, ∥Molecular Structure, and ⊥Oncology Research, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States, and Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Patrick Eden
- †Departments of Medicinal Chemistry, ‡Pharmaceutical Research and Development, §Pharmacokinetics and Drug Metabolism, ∥Molecular Structure, and ⊥Oncology Research, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States, and Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Kelly Hanestad
- †Departments of Medicinal Chemistry, ‡Pharmaceutical Research and Development, §Pharmacokinetics and Drug Metabolism, ∥Molecular Structure, and ⊥Oncology Research, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States, and Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Liyue Huang
- †Departments of Medicinal Chemistry, ‡Pharmaceutical Research and Development, §Pharmacokinetics and Drug Metabolism, ∥Molecular Structure, and ⊥Oncology Research, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States, and Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Min-Hwa Jasmine Lin
- †Departments of Medicinal Chemistry, ‡Pharmaceutical Research and Development, §Pharmacokinetics and Drug Metabolism, ∥Molecular Structure, and ⊥Oncology Research, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States, and Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Jin Tang
- †Departments of Medicinal Chemistry, ‡Pharmaceutical Research and Development, §Pharmacokinetics and Drug Metabolism, ∥Molecular Structure, and ⊥Oncology Research, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States, and Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Beth Ziegler
- †Departments of Medicinal Chemistry, ‡Pharmaceutical Research and Development, §Pharmacokinetics and Drug Metabolism, ∥Molecular Structure, and ⊥Oncology Research, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States, and Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Robert Radinsky
- †Departments of Medicinal Chemistry, ‡Pharmaceutical Research and Development, §Pharmacokinetics and Drug Metabolism, ∥Molecular Structure, and ⊥Oncology Research, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States, and Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Richard Kendall
- †Departments of Medicinal Chemistry, ‡Pharmaceutical Research and Development, §Pharmacokinetics and Drug Metabolism, ∥Molecular Structure, and ⊥Oncology Research, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States, and Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Vinod F Patel
- †Departments of Medicinal Chemistry, ‡Pharmaceutical Research and Development, §Pharmacokinetics and Drug Metabolism, ∥Molecular Structure, and ⊥Oncology Research, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States, and Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Marc Payton
- †Departments of Medicinal Chemistry, ‡Pharmaceutical Research and Development, §Pharmacokinetics and Drug Metabolism, ∥Molecular Structure, and ⊥Oncology Research, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States, and Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| |
Collapse
|
7
|
Canon J, Osgood T, Olson SH, Saiki AY, Robertson R, Yu D, Eksterowicz J, Ye Q, Jin L, Chen A, Zhou J, Cordover D, Kaufman S, Kendall R, Oliner JD, Coxon A, Radinsky R. The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents. Mol Cancer Ther 2015; 14:649-58. [PMID: 25567130 DOI: 10.1158/1535-7163.mct-14-0710] [Citation(s) in RCA: 88] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2014] [Accepted: 12/22/2014] [Indexed: 11/16/2022]
Abstract
p53 is a critical tumor suppressor and is the most frequently inactivated gene in human cancer. Inhibition of the interaction of p53 with its negative regulator MDM2 represents a promising clinical strategy to treat p53 wild-type tumors. AMG 232 is a potential best-in-class inhibitor of the MDM2-p53 interaction and is currently in clinical trials. We characterized the activity of AMG 232 and its effect on p53 signaling in several preclinical tumor models. AMG 232 binds the MDM2 protein with picomolar affinity and robustly induces p53 activity, leading to cell-cycle arrest and inhibition of tumor cell proliferation. AMG 232 treatment inhibited the in vivo growth of several tumor xenografts and led to complete and durable regression of MDM2-amplified SJSA-1 tumors via growth arrest and induction of apoptosis. Therapeutic combination studies of AMG 232 with chemotherapies that induce DNA damage and p53 activity resulted in significantly superior antitumor efficacy and regression, and markedly increased activation of p53 signaling in tumors. These preclinical data support the further evaluation of AMG 232 in clinical trials as both a monotherapy and in combination with standard-of-care cytotoxics.
Collapse
Affiliation(s)
- Jude Canon
- Department of Oncology Research, Amgen Inc., Thousand Oaks, California.
| | - Tao Osgood
- Department of Oncology Research, Amgen Inc., Thousand Oaks, California
| | - Steven H Olson
- Department of Medicinal Chemistry, Amgen Inc., San Francisco, California
| | - Anne Y Saiki
- Department of Oncology Research, Amgen Inc., Thousand Oaks, California
| | - Rebecca Robertson
- Department of Oncology Research, Amgen Inc., Thousand Oaks, California
| | - Dongyin Yu
- Department of Oncology Research, Amgen Inc., Thousand Oaks, California
| | - John Eksterowicz
- Department of Molecular Structure, Amgen Inc., San Francisco, California
| | - Qiuping Ye
- Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., San Francisco, California
| | - Lixia Jin
- Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., San Francisco, California
| | - Ada Chen
- Department of Molecular Structure, Amgen Inc., San Francisco, California
| | - Jing Zhou
- Department of Molecular Structure, Amgen Inc., San Francisco, California
| | - David Cordover
- Department of Pathology, Amgen Inc., Thousand Oaks, California
| | - Stephen Kaufman
- Department of Pathology, Amgen Inc., Thousand Oaks, California
| | - Richard Kendall
- Department of Oncology Research, Amgen Inc., Thousand Oaks, California
| | - Jonathan D Oliner
- Department of Oncology Research, Amgen Inc., Thousand Oaks, California
| | - Angela Coxon
- Department of Oncology Research, Amgen Inc., Thousand Oaks, California
| | - Robert Radinsky
- Department of Oncology Research, Amgen Inc., Thousand Oaks, California
| |
Collapse
|
8
|
Juan G, Bush TL, Ma C, Manoukian R, Chung G, Hawkins JM, Zoog S, Kendall R, Radinsky R, Loberg R, Friberg G, Payton M. AMG 900, a potent inhibitor of aurora kinases causes pharmacodynamic changes in p-Histone H3 immunoreactivity in human tumor xenografts and proliferating mouse tissues. J Transl Med 2014; 12:307. [PMID: 25367255 PMCID: PMC4221688 DOI: 10.1186/s12967-014-0307-x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2014] [Accepted: 10/22/2014] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND The Aurora family of serine-threonine kinases are essential regulators of cell division in mammalian cells. Aurora-A and -B expression and kinase activity is elevated in a variety of human cancers and is associated with high proliferation rates and poor prognosis. AMG 900 is a highly potent and selective pan-aurora kinase inhibitor that has entered clinical evaluation in adult patients with advanced cancers. In mice, oral administration of AMG 900 blocks the phosphorylation of histone H3 on serine-10 (p-Histone H3), a proximal substrate of aurora-B and inhibits the growth of multiple human tumor xenografts, including multidrug-resistant models. METHODS In order to establish a preclinical pharmacokinetic-pharmacodynamic (PK-PD) relationship for AMG 900 that could be translated to the clinic, we used flow cytometry and laser scanning cytometry detection platforms to assess the effects on p-Histone H3 inhibition in terms of sensitivity, precision, and specificity, in human tumor xenografts in conjunction with mouse skin and bone marrow tissues. Mice with established COLO 205 tumors were administered AMG 900 at 3.75, 7.5, and 15 mg/kg and assessed after 3 hours. RESULTS Significant suppression of p-Histone H3 in mouse skin was only observed at 15 mg/kg (p <0.0001), whereas in mouse bone marrow and in tumor a dose-dependent inhibition was achieved at all three doses (p ≤ 0.00015). These studies demonstrate that AMG 900 inhibits p-Histone H3 in tumors and surrogate tissues (although tissues such as skin may be less sensitive for assessing PD effects). To further extend our work, we evaluated the feasibility of measuring p-Histone H3 using fine-needle aspirate (FNA) tumor xenograft biopsies. Treatment with AMG 900 significantly inhibited p-Histone H3 (>99% inhibition, p <0.0001) in COLO 205 tumors. Lastly, we illustrate this LSC-based approach can detect p-Histone H3 positive cells using mock FNAs from primary human breast tumor tissues. CONCLUSION Phosphorylation of histone H3 is a useful biomarker to determine the pharmacodynamics (PD) activity of AMG 900. FNA biopsies may be a viable approach for assessing AMG 900 PD effects in the clinic.
Collapse
Affiliation(s)
- Gloria Juan
- />Departments of Oncology Biomarkers and Early Development, Thousand Oaks, CA 91320 USA
| | - Tammy L Bush
- />Departments of Oncology Research, Thousand Oaks, CA 91320 USA
| | - Connie Ma
- />Departments of Oncology Biomarkers and Early Development, Thousand Oaks, CA 91320 USA
| | - Raffi Manoukian
- />Departments of Oncology Biomarkers and Early Development, Thousand Oaks, CA 91320 USA
| | - Grace Chung
- />Departments of Oncology Research, Thousand Oaks, CA 91320 USA
| | - Jennifer M Hawkins
- />Department of Pathology, Amgen Inc, One Amgen Center Drive, Thousand Oaks, CA 91320 USA
| | - Stephen Zoog
- />Departments of Oncology Biomarkers and Early Development, Thousand Oaks, CA 91320 USA
| | - Richard Kendall
- />Departments of Oncology Research, Thousand Oaks, CA 91320 USA
| | - Robert Radinsky
- />Departments of Oncology Research, Thousand Oaks, CA 91320 USA
| | - Robert Loberg
- />Departments of Oncology Biomarkers and Early Development, Thousand Oaks, CA 91320 USA
| | - Greg Friberg
- />Departments of Oncology Biomarkers and Early Development, Thousand Oaks, CA 91320 USA
| | - Marc Payton
- />Departments of Oncology Research, Thousand Oaks, CA 91320 USA
| |
Collapse
|
9
|
Moody G, Beltran PJ, Mitchell P, Cajulis E, Chung YA, Hwang D, Kendall R, Radinsky R, Cohen P, Calzone FJ. IGF1R blockade with ganitumab results in systemic effects on the GH-IGF axis in mice. J Endocrinol 2014; 221:145-55. [PMID: 24492468 PMCID: PMC4160154 DOI: 10.1530/joe-13-0306] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Ganitumab is a fully human MAB to the human type 1 IGF receptor (IGF1R). Binding assays showed that ganitumab recognized murine IGF1R with sub-nanomolar affinity (KD=0.22 nM) and inhibited the interaction of murine IGF1R with IGF1 and IGF2. Ganitumab inhibited IGF1-induced activation of IGF1R in murine lungs and CT26 murine colon carcinoma cells and tumors. Addition of ganitumab to 5-fluorouracil resulted in enhanced inhibition of tumor growth in the CT26 model. Pharmacological intervention with ganitumab in naïve nude mice resulted in a number of physiological changes described previously in animals with targeted deletions of Igf1 and Igf1r, including inhibition of weight gain, reduced glucose tolerance and significant increase in serum levels of GH, IGF1 and IGFBP3. Flow cytometric analysis identified GR1/CD11b-positive cells as the highest IGF1R-expressing cells in murine peripheral blood. Administration of ganitumab led to a dose-dependent, reversible decrease in the number of peripheral neutrophils with no effect on erythrocytes or platelets. These findings indicate that acute IGF availability for its receptor plays a critical role in physiological growth, glucose metabolism and neutrophil physiology and support the presence of a pituitary IGF1R-driven negative feedback loop that tightly regulates serum IGF1 levels through Gh signaling.
Collapse
Affiliation(s)
- Gordon Moody
- Oncology Research Therapeutic Area, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, USA David Geffen School of Medicine, Los Angeles, California, USA USC Davis School of Gerontology, Los Angeles, California, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Bush TL, Payton M, Heller S, Chung G, Hanestad K, Rottman JB, Loberg R, Friberg G, Kendall RL, Saffran D, Radinsky R. AMG 900, a small-molecule inhibitor of aurora kinases, potentiates the activity of microtubule-targeting agents in human metastatic breast cancer models. Mol Cancer Ther 2013; 12:2356-66. [PMID: 23990115 DOI: 10.1158/1535-7163.mct-12-1178] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Breast cancer is the most prevalent malignancy affecting women and ranks second in cancer-related deaths, in which death occurs primarily from metastatic disease. Triple-negative breast cancer (TNBC) is a more aggressive and metastatic subtype of breast cancer that is initially responsive to treatment of microtubule-targeting agents (MTA) such as taxanes. Recently, we reported the characterization of AMG 900, an orally bioavailable, potent, and highly selective pan-Aurora kinase inhibitor that is active in multidrug-resistant cell lines. In this report, we investigate the activity of AMG 900 alone and in combination with two distinct classes of MTAs (taxanes and epothilones) in multidrug-resistant TNBC cell lines and xenografts. In TNBC cells, AMG 900 inhibited phosphorylation of histone H3 on Ser(10), a proximal substrate of Aurora-B, and induced polyploidy and apoptosis. Furthermore, AMG 900 potentiated the antiproliferative effects of paclitaxel and ixabepilone at low nanomolar concentrations. In mice, AMG 900 significantly inhibited the growth of MDA-MB-231 (F(11); parental), MDA-MB-231 (F(11)) PTX-r (paclitaxel-resistant variant), and DU4475 xenografts. The combination of AMG 900 with docetaxel enhanced tumor inhibition in MDA-MB-231 (F(11)) xenografts compared with either monotherapy. Notably, combining AMG 900 with ixabepilone resulted in regressions of MDA-MB-231 (F(11)) PTX-r xenografts, in which more than 50% of the tumors failed to regrow 75 days after the cessation of drug treatment. These findings suggest that AMG 900, alone and in combination with MTAs, may be an effective intervention strategy for the treatment of metastatic breast cancer and provide potential therapeutic options for patients with multidrug-resistant tumors.
Collapse
Affiliation(s)
- Tammy L Bush
- Corresponding Author: Tammy L. Bush, Amgen Inc., 360 Binney Street, Mailstop 7-G-12, Cambridge, MA 02142.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Rex K, Lewis XZ, Gobalakrishnan S, Glaus C, Silva MD, Radinsky R, Burgess TL, Gambhir SS, Coxon A. Evaluation of the antitumor effects of rilotumumab by PET imaging in a U-87 MG mouse xenograft model. Nucl Med Biol 2013; 40:458-63. [DOI: 10.1016/j.nucmedbio.2013.01.004] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2012] [Accepted: 01/15/2013] [Indexed: 01/03/2023]
|
12
|
Bready JV, Kaplan-Lefko P, Moriguchi J, Payton M, Kaufman S, Oliner J, Radinsky R, Coxon A. Abstract 5089: Combined treatment of trebananib (AMG 386) with panitumumab in preclinical tumor models. Cancer Res 2013. [DOI: 10.1158/1538-7445.am2013-5089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Cancer therapies that combine agents directly targeting tumor cells with those impacting the tumor stroma hold the promise of improving patient outcomes. In this preclinical study, we examined the effects of inhibiting both EGF signaling in human tumor cells and angiopoietin signaling in the murine stroma. Using tumor xenograft models, we tested a treatment combination of panitumumab, a fully human monoclonal antibody against human EGF receptor, and trebananib, an investigational peptide-Fc fusion protein that prevents binding of angiopoietins 1 and 2 to their receptor, Tie2. We assessed the effect of this combination on tumor growth and explored mechanisms of enhanced efficacy.
Methods: Athymic nude mice were injected SC in the right flank with either 1x107 A431 (human epidermoid carcinoma) or 5x106 DLD-1 (colon adenocarcinoma) cells. When tumors were ∼ 200 mm3, 20 μg panitumumab IP and/or 70 μg trebananib SC were given twice weekly. Controls were isotype antibody or human Fc. In mechanism of action studies, DLD-1 tumors (∼ 300-400 mm3) received 2 treatments over 5 days before harvest and processing for paraffin sectioning. To examine endothelial cell proliferation, treated tumors were enzyme-digested and stained with anti-CD31, anti-CD45, and anti-BrdU antibodies. The percentage of BrdU-positive tumor-associated endothelial cells (CD31high/CD45neg) was determined by flow cytometry.
Results: In both tumor models, combined treatment with panitumumab and trebananib resulted in significantly greater tumor growth inhibition (p≤0.014) than treatment with either single agent alone. All treatments were well tolerated; no significant weight loss was observed. Mechanistic studies revealed that combination treatment did not alter the single-agent activity of either treatment: histological analyses showed a significant reduction in estimated blood vessel area within viable tumor after treatment with either trebananib (p=0.0006) or panitumumab (p=0.012) alone; this reduction was not affected by combination treatment. Similarly, BrdU incorporation assays demonstrated that single-agent panitumumab significantly impaired tumor cell proliferation (p=0.0003), whereas single-agent trebananib significantly reduced endothelial cell proliferation (p<0.0001). Combined treatment did not change the effects on cell proliferation seen with either single agent alone.
Conclusions: This study demonstrates that combined treatment with agents targeting EGF signaling in the tumor and angiopoietin signaling in the stroma results in significantly enhanced antitumor activity. Neither agent appears to impact the biochemical activities of the other, but instead gives rise to an orthogonal enhancement of antitumor activities. These findings support further clinical testing of agents that target the tumor stroma in combination with direct tumor-targeting therapies.
Citation Format: James V. Bready, Paula Kaplan-Lefko, Jodi Moriguchi, Marc Payton, Stephen Kaufman, Jonathan Oliner, Robert Radinsky, Angela Coxon. Combined treatment of trebananib (AMG 386) with panitumumab in preclinical tumor models. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 5089. doi:10.1158/1538-7445.AM2013-5089
Collapse
|
13
|
Moody GE, Belmontes B, King C, Liu S, Masterman S, Murawsky C, Tsuruda T, Wang W, Radinsky R, Beltran PJ. Abstract 5158: Generation of a fully human Gas6 neutralizing antibody with anti-tumor activity in vivo. Cancer Res 2013. [DOI: 10.1158/1538-7445.am2013-5158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Growth arrest specific 6 (Gas6) is a vitamin-K dependent protein that is involved in the regulation of a wide array of cellular activities, including adhesion, migration, immune evasion, and apoptosis. Gas6 as well as its receptors Axl, Mer, and Tyro3 are highly expressed in multiple malignancies suggesting that signaling through this axis may be tumor promoting in human disease. A strategy was devised to generate fully human neutralizing antibodies against Gas6 using XenoMouse technology. Hybridoma supernatants were first screened for their ability to bind Gas6, then for their ability to inhibit Gas6 binding to the Axl receptor and block Gas6-induced Axl phosphorylation in human cells. Two purified antibodies isolated from the screened hybridomas, 1D9.1 and 1G9.1, maintained potency in all 3 assays and also inhibited Gas6-induced cellular migration and proliferation. In the scratch wound migration assay, the antibodies inhibited both basal and Gas6-induced wound closure to a greater extent than the soluble extracellular domain of the receptor Axl (Axl- Fc). In the proliferation assay, the antibody 1D9.1 completely inhibited Gas6-induced proliferation with a half maximal effective concentration (EC50) of 0.15nM. In vivo characterization of one of the antibodies, 1D9.1, was conducted using a pharmacodynamic (PD) assay that measured the ability of the antibody to inhibit Gas6-induced Akt activation in the mouse spleen. Treatment of mice with a single dose (100-1000 μg) of 1D9.1 led to greater than 90% inhibition of Gas6-induced phosphorylated Akt (pAkt) for up to 72 hours. Based on the target coverage observed in the PD assay, we tested the efficacy of 1D9.1 against Panc-1 human pancreatic adenocarcinoma xenografts implanted in athymic nu/nu female mice. At doses of 50 and 150 μg, twice weekly, the Gas6 neutralizing antibody 1D9.1 was able to inhibit 55% and 76% of tumor growth, respectively. (p<0.001 for both treatments vs. control Ig). When combined with gemcitabine, 1D9.1 was able to inhibit tumor growth to a greater extent than either agent alone (p<0.001 vs. either monotherapy). Together, the data suggest that Gas6 neutralization should be further explored as a potential strategy for the treatment of pancreatic cancer.
Citation Format: Gordon E. Moody, Brian Belmontes, Chadwick King, Shuying Liu, Stephanie Masterman, Chris Murawsky, Trace Tsuruda, Wei Wang, Robert Radinsky, Pedro J. Beltran. Generation of a fully human Gas6 neutralizing antibody with anti-tumor activity in vivo. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 5158. doi:10.1158/1538-7445.AM2013-5158
Collapse
|
14
|
Price J, Fabra A, Zhang R, Radinsky R, Pathak S. Characterization of variants of a human breast-cancer cell-line isolated from metastases in different organs of nude-mice. Int J Oncol 2012; 5:459-67. [PMID: 21559598 DOI: 10.3892/ijo.5.3.459] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The MDA-MB-435 human breast cancer cell line metastasizes from tumors growing in the mammary fatpad of nude mice; metastases are found in the lymph nodes and lungs of 75 to 100% of tumor-bearing mice, and at a lower incidence in other organs such as the heart, skeletal muscle, adrenal gland and brain. Variants of this breast cancer cell line were established from metastases in different organs, including the lungs and brain of nude mice; these lines were designated 435-Lung2 and 435-Br1, respectively. Karyotypic analysis of the new variants suggested a clonal origin for the different organ metastases. The lung-derived cells were as metastatic as the original cell line when re-injected in nude mice, yet the cells from the brain metastasis produced few metastases. Analyses of the invasive potential of the cell lines showed that they did not differ in expression of mRNA for 72-kDa type IV-collagenase, or in gelatinase activity (by zymography), or in ability to invade through a Matrigel-coated filter. The poorly metastatic 435-Br1 cells showed reduced binding to cultured monolayers of mouse lung-endothelial cells, compared with the metastatic 435-Lung2 and MDA-MB-435 cells. When the breast cancer cells were artificially arrested in the lungs of nude mice, by injecting Cytodex beads coated with cells, all three cell lines grew equally well, suggesting that the deficiency found in the metastatic potential of the 435-Br1 cells may be associated with interactions with endothelial cells, rather than growth potential in the lungs. Further comparisons of these two metastasis-derived variants of a heterogeneous cell line will lead to greater understanding of the metastatic phenotype of human breast cancer.
Collapse
|
15
|
Fujimaki T, Ellis L, Bucana C, Radinsky R, Price J, Fidler I. Simultaneous radiolabel, genetic tagging and proliferation assays to study the organ distribution and fate of metastatic cells. Int J Oncol 2012; 2:895-901. [PMID: 21573644 DOI: 10.3892/ijo.2.6.895] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
We compared the suitability of 3 techniques to study tumor cell survival in the lungs of mice and proliferation into metastases. Genetic tagging of tumor cells with the bacterial beta-galactosidase marker gene lacZ, radiolabeling of tumor cells with [I-125]IdUrd, and S-phase labeling of cells with bromodeoxyuridine (BrdUrd) were used simultaneously to track the fate of highly metastatic K-1735 X-21 melanoma cells injected into syngeneic C3H/HeN mice. The melanoma cells were transfected with a plasmid containing lacZ and neomycin resistance genes. After growth in selective medium, the cells were incubated in medium containing [I-125]IdUrd and then injected i.v. into mice. Lungs isolated at various times after i.v. injection were processed for staining with X-gal, radioactive monitoring, and immunohistochemical staining with a monoclonal antibody against BrdUrd. At early time points, the presence of lacZ-positive cells directly correlated with radioactivity associated with viable cells. However, the expression of the beta-galactosidase was only stable for 1 week, and by 3 weeks after injection, large metastases contained only a few lacZ-positive cells. The combination of lacZ tagging with BrdUrd proliferation assay accurately identified dividing tumor cells in micrometastases. The simultaneous use of these 3 techniques allowed us to conclude that quantitative analysis of tumor cell survival is best accomplished by radioactive labeling of cells, whereas the use of lacZ-tagged cells allowed for studies of localization. Analysis of tumor cell proliferation requires the use of both lacZ tagging and immunohistochemistry using anti-BrdUrd antibodies. Since the process of metastasis consists of a series of distinct steps, each technique presents its own advantages and limitations.
Collapse
Affiliation(s)
- T Fujimaki
- UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CELL BIOL,HMB 173,1515 HOLCOMBE BLVD,HOUSTON,TX 77030
| | | | | | | | | | | |
Collapse
|
16
|
Wilmanns C, Fan D, Obrian C, Radinsky R, Bucana C, Tsan R, Fidler I. Modulation of Doxorubicin sensitivity and level of p-glycoprotein expression in human colon-carcinoma cells by ectopic and orthotopic environments in nude-mice. Int J Oncol 2012; 3:413-22. [PMID: 21573380 DOI: 10.3892/ijo.3.3.413] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The purpose of the study was to determine whether the organ environment can influence the response of colon cancer cells to chemotherapy. The highly metastatic human colon cancer cell line KM12L4, previously selected for production of liver metastases in nude mice, was injected into the cecal wall and into the spleen to produce liver metastases, and into the subcutis of nude mice. Doxorubicin (DOX) at 10 mg/kg or saline (control) was injected intravenously on days 7 and 16 after tumor cell injection. The in vivo response of tumors growing in the cecum, liver, and subcutaneous (s.c.) sites as well as the DOX sensitivity of cell lines established from liver and s.c. tumors were compared. Colon cancers growing s.c. were more sensitive to DOX than tumors growing in the cecal wall or liver of nude mice. The difference in response to DOX between s.c. tumors (sensitive) and liver tumors (resistant) was not due to selection of cell populations with different sensitivity to DOX, or differences in DOX distribution. PKC activity was lower in tumors of the liver and the cecum than in s.c. tumors. The expression of P-glycoprotein as determined by flow cytometric analysis of tumor cells harvested from lesions in different organs correlated inversely with their sensitivity to DOX. Increased levels of P-glycoprotein correlated with mdr-1, mdr-3 mRNA expression as determined by Northern analysis. Collectively, the data show that the organ environment influences the response of human colon carcinoma cells to DOX and recommend that animal models of this disease for experimental therapeutic studies employ orthotopic implantation of tumor cells.
Collapse
Affiliation(s)
- C Wilmanns
- UNIV TEXAS,M D ANDERSON CANC CTR,DEPT CELL BIOL,HMB 173,1515 HOLCOMBE BLVD,HOUSTON,TX 77030
| | | | | | | | | | | | | |
Collapse
|
17
|
Koura A, Vangolen K, Tsan R, Radinsky R, Price J, Ellis L. Regulation of genes associated with angiogenesis, growth, and metastasis by specific p53 point mutations in a murine melanoma cell line. Oncol Rep 2012; 4:475-9. [PMID: 21590080 DOI: 10.3892/or.4.3.475] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
K1735 murine melanoma cells transfected with p53 cDNAs bearing specific point mutations are metastatic in nude mice, whereas the parent and control-transfected cells are nonmetastatic. To determine whether p53 gene mutations regulate genes associated with angiogenesis, growth, and metastasis, we examined expression of vascular endothelial growth factor I, IGF-I receptor, epidermal growth factor insulin-like growth factor I, IGF-I receptor, epidermal growth factor receptor, c-MET, and thrombospondin 1 in K1735 cells transfected with one of four different mutant p53 cDNAs. Northern blot analysis demonstrated differential upregulation of these genes in cells transfected with different mutant p53 cDNAs. Up-regulation of angiogenesis-, growth-, and metastasis-related genes by mutant p53 may contribute to metastasis formation.
Collapse
Affiliation(s)
- A Koura
- UNIV TEXAS,MD ANDERSON CANC CTR,DEPT SURG ONCOL,HOUSTON,TX 77030. UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CELL BIOL,HOUSTON,TX 77030
| | | | | | | | | | | |
Collapse
|
18
|
Freeman DJ, McDorman K, Ogbagabriel S, Kozlosky C, Yang BB, Doshi S, Perez-Ruxio JJ, Fanslow W, Starnes C, Radinsky R. Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer. Mol Cancer 2012; 11:47. [PMID: 22830443 PMCID: PMC3499177 DOI: 10.1186/1476-4598-11-47] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2012] [Accepted: 07/10/2012] [Indexed: 01/21/2023] Open
Abstract
Background Successful treatment of solid tumors relies on the ability of drugs to penetrate into the tumor tissue. Methods We examined the correlation of panitumumab (an anti-epidermal growth factor [EGFR] antibody) tumor penetration and EGFR saturation, a potential obstacle in large molecule drug delivery, using pharmacokinetics, pharmacodynamics, and tumor growth rate in an A431 epidermoid carcinoma xenograft model of human cancer. To determine receptor saturation, receptor occupancy, and levels of proliferation markers, immunohistochemical and flow cytometric methods were used. Pharmacokinetic data and modeling were used to calculate growth characteristics of panitumumab-treated tumors. Results Treatment with panitumumab in vivo inhibited pEGFR, Ki67 and pMAPK levels vs control. Tumor penetration and receptor saturation were dose- and time-dependent, reaching 100% and 78%, respectively. Significant tumor inhibition and eradication (p < 0.05) were observed; plasma concentration associated with tumor eradication was estimated to be 0.2 μg/ml. The tumor inhibition model was able to describe the mean tumor growth and death rates. Conclusions These data demonstrate that the antitumor activity of panitumumab correlates with its ability to penetrate into tumor tissue, occupy and inhibit activation of EGFR, and inhibit markers of proliferation and MAPK signaling.
Collapse
|
19
|
Freeman D, Ogbagabriel S, Xie J, Gloria J, Potter N, Dekeyser J, Radinsky R. P-0199 Mechanisms Mediating The Negative Interaction Between Oxaliplatin and Epidermal Growth Factor Receptor Inhibitors in Patients With KRAS Mutant Colorectal Cancer. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)30124-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
20
|
Freeman DJ, Ogbagabriel S, Xie J, Juan G, Potter N, Dekeyser J, Radinsky R. Mechanisms mediating the negative interaction between oxaliplatin (Ox) and epidermal growth factor receptor (EGFR) inhibitors in patients (pts) with KRAS mutant (MT) colorectal cancer (CRC). J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.15_suppl.3580] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3580 Background: Phase 3 trials have shown that pts with MT KRAS tumors have shorter progression-free survival and overall survival when an EGFR inhibitor is added to Ox-containing chemotherapy (CT) (Bokemeyer et al 2011, Douillard et al 2010). However, KRAS status alone is not predictive of pt outcomes in this setting. The negative interaction has not been observed in pts with wild-type (WT) KRAS tumors receiving an EGFR inhibitor and platinum-CT or with MT KRAS tumors receiving an EGFR inhibitor with irinotecan (Peeters et al 2010, Van Cutsem et al 2009). Our goal was to understand the pharmacodynamic interaction between EGFR inhibitors and Ox in KRAS MT CRC cells. Methods: Isogenic MT and WT KRAS-expressing HCT116 CRC cells were treated with Ox, SN-38 (the active metabolite of irinotecan), panitumumab, gefitinib, or inhibitors of MEK, PI3K or Src as single agents or in combination. Viability was measured using an ATPlite assay. Cellular distribution of EGFR was visualized by a confocal microscopy. Downstream activation of MAPK and PI3K was detected by Western blotting. Results: Treatment (tx) with gefitinib, but not panitumumab, reversed the anti-proliferative effects of Ox in the MT KRAS-expressing CRC cells vs Ox alone (p<0.0005) despite no differences in the number of platinum-DNA adducts. Neither tx reversed the anti-proliferative effects of Ox observed in the WT KRAS-expressing cells or SN-38 in either the MT or WT KRAS-expressing cells. EGFR was predominantly expressed in the cytoplasm of KRAS MT cells vs on the cell surface in the KRAS WT cells, which may explain the inability of panitumumab to reverse the anti-proliferative effects of Ox in the CRC cells. Combination tx of MT KRAS CRC cells with Ox and gefitinib increased pAKT which was not observed with Ox alone. Tx of the MT KRAS-expressing cells with a MEK, PI3K or Src inhibitor reversed the negative interaction between Ox and gefitinib (p<0.0005). Conclusions: Feedback though AKT may contribute to the increased resistance to Ox in KRAS MT cells. Inhibitors of MEK, PI3K, or Src reversed the negative interaction between the EGFR inhibitors and Ox in a MT-KRAS genetic background.
Collapse
|
21
|
Zhang N, Caenepeel S, Wang L, Norman M, Kendall R, Burgess T, Radinsky R, Hughes P, Freeman DJ. Abstract 2797: AMG 511, a potent and selective class I PI3K inhibitor, demonstrates anti-tumor activity in multiple xenograft models. Cancer Res 2012. [DOI: 10.1158/1538-7445.am2012-2797] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Constitutive activation of the phosphoinositide 3-kinases (PI3K) signaling pathway is a frequent event in many cancers and results in increased cell growth and survival. Therefore, PI3K is an attractive target for oncology. This study evaluated the correlation between the pharmacokinetics (PK) and pharmacodynamics (PD) of AMG 511, a potent and selective class I PI3K inhibitor, and anti-tumor activity in preclinical models of human cancer which harbor mutations in the PI3K pathway. Method: To determine the PD, PK, and efficacy relationship of AMG 511, U87 MG (PTEN null), HCT-116 (PI3K & KRAS mutant), or BT474 (PI3K mutant, HER2 amplified) tumor bearing mice were treated with up to 10 mpk AMG 511 daily by oral gavage. For tumor PD time course and dose response studies, AKT phosphorylation (pAKT) was measured using an electrochemiluminescence detection assay after a single-dose of AMG 511 in U87 MG tumor bearing mice. To determine in vivo efficacy, mice bearing established U87 MG, HCT-116, or BT474 tumors were treated daily and measured 2x/week. The mechanism of action of AMG 511 was determined by examining effects on cell proliferation (BrdU incorporation) and apoptosis (caspase staining) using a combination of immunohistochemistry and flow cytometry analyses of ex-vivo U87 MG xenograft tumors following treatment with AMG 511. Results: Inhibition of pAKT in U87 MG tumor tissue was associated with increased plasma concentration of AMG 511 after a single dose (EC50=59 ng/mL). Treatment with 0.3, 1, and 3 mpk AMG 511 inhibited pAKT in tumor tissue by 39, 81, and 92 %, respectively. Treatment with 10 mpk AMG 511 significantly inhibited pAKT up to 16 hrs (p<0.01). A dose-dependent inhibition of xenograft growth was observed with AMG 511 versus vehicle control in multiple tumor xenograft models with PI3K pathway mutations (p<0.03). Flow cytometry analysis demonstrated that AMG 511 treatment resulted in a dose-dependent decrease of BrdU incorporation in tumor and CD31 positive endothelial cells at peak and trough plasma levels (p<0.05). Immunohistochemical analysis confirmed that AMG 511 treatment induced tumor cell apoptosis as measured by caspase staining in U87 MG tumor samples. Conclusion: AMG 511 is a potent pan-PI3K inhibitor, which has significant anti-tumor activity in human tumor xenograft models which harbor PI3K pathway mutations. Tumor growth inhibition is the result of an increase in AMG 511 exposure, a reduction in PI3K signaling, an inhibition of tumor cell and endothelial cell proliferation and an induction of tumor cell apoptosis. These data together provide evidence for the potential clinical investigation of AMG 511 in patients whose tumors harbor mutations in the PI3K pathway.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2797. doi:1538-7445.AM2012-2797
Collapse
|
22
|
Caenepeel S, Zhang N, Wang L, Norman MH, Burgess T, Radinsky R, Kendall R, Freeman D, Hughes PE. Abstract 2805: In vitro characterization of AMG 511, a potent and selective class I PI3K inhibitor for the treatment of cancer. Cancer Res 2012. [DOI: 10.1158/1538-7445.am2012-2805] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The PI3K signaling pathway is frequently activated in cancer and has been implicated in many aspects of tumor growth and survival. Inhibition of this pathway represents a potential therapeutic path for the treatment of cancer. This study evaluated the in vitro characteristics of AMG 511, a potent and selective pan class I PI3K inhibitor exhibiting IC50 values of 8, 11, 2, and 6 nM against the PI3K β, α, β, and ≤ isoforms respectively. AMG 511 was shown to be inactive against members of the closely related phosphoinositide 3 kinase related kinases (PIKK) family of kinases and did not inhibit mTOR, hVPS34, PI4Kα or PI4Kα in-vitro (IC50 values > 1 μM). In addition, AMG 511 was inactive against a majority of protein kinases (372) in the human kinome as measured by in-vitro binding assays. AMG 511 inhibited PI3K pathway signaling in U87 MG glioblastoma cells as determined by dose-dependent reduction in AKT S473 phosphorylation (IC50 = 4 nM). AKT inhibition resulted in a concomitant reduction in PRAS40 phosphorylation (IC50 = 23 nM), a downstream effector of AKT. Reduced phosphorylation of mTORC1 substrates p70S6K (IC50 = 30 nM) and S6 (IC50 = 70 nM) but not 4EBP1 (T37/46), was also detected in U87 MG cells, suggesting that upstream blockade of PI3K pathway signaling with AMG 511 treatment leads to a selective reduction in downstream mTORC1 activity. Given the well documented role of mTORC1 in cap-dependent translation we profiled AMG 511 in a methionine-analog incorporation assay in U87 MG cells. However, no significant inhibition of bulk translation was observed following treatment with AMG 511 in U87 MG cells. Treatment of U87 MG cells with AMG 511 revealed a pronounced G1 arrest with a concurrent reduction in BrdU+ cells, detectable within 8 hours of treatment. This anti-proliferative effect was fully reversible by 18 hours following washout. In line with these anti-proliferative effects, reduced cyclin D1 levels and elevated p27 levels were detected within 4 hours of treatment. Minimal cell killing effects were detected with AMG 511 treatment in U87 MG cells as measured by induction of cleaved caspase-3 and DNA content < 2N. AMG 511 was profiled across a large panel of tumor cell lines encompassing several tumor types including breast and lung. A majority of the cell lines tested exhibited sensitivity to AMG 511 with a subset exhibiting evidence for cell death upon treatment with AMG 511. Breast cancer cell lines harboring activating mutations in PI3Kα, loss of PTEN, or amplification of Her2 tended to show greater sensitivity to AMG 511 treatment. In conclusion, AMG 511 is a potent and selective pan class I PI3K inhibitor, capable of inhibiting PI3K signaling and inducing robust anti-proliferative effects via a G1 arrest in many tumor cell lines, with evidence of cell killing in a subset of lines.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2805. doi:1538-7445.AM2012-2805
Collapse
|
23
|
Coxon A, Bready J, Kaufman S, Estrada J, Osgood T, Canon J, Wang L, Radinsky R, Kendall R, Hughes P, Polverino A. Anti-tumor activity of motesanib in a medullary thyroid cancer model. J Endocrinol Invest 2012; 35:181-90. [PMID: 21422803 DOI: 10.3275/7609] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
BACKGROUND Medullary thyroid cancer (MTC) is frequently associated with mutations in the tyrosine kinase Ret and with increased expression of vascular endothelial growth factor (VEGF) and VEGF receptor 2 (VEGFR2). Motesanib is an investigational, orally administered small molecule antagonist of VEGFR1, 2, and 3; platelet-derived growth factor receptor (PDGFR); Kit; and possibly Ret. AIM The aim of this study was to investigate the effects of motesanib on wildtype and mutant Ret activity in vitro and on tumor xenograft growth in a mouse model of MTC. METHODS/RESULTS In cellular phosphorylation assays, motesanib inhibited the activity of wild-type Ret (IC(50)=66 nM), while it had limited activity against mutant Ret C634W (IC(50)=1100 nM) or Ret M918T (IC(50)>2500 nM). In vivo, motesanib significantly inhibited the growth of TT tumor cell xenografts (expressing Ret C634W) and significantly reduced tumor blood vessel area and tumor cell proliferation, compared with control. Treatment with motesanib resulted in substantial inhibition of Ret tyrosine phosphorylation in TT xenografts and, at comparable doses, in equivalent inhibition of VEGFR2 phosphorylation in both TT xenografts and in mouse lung tissue. CONCLUSIONS The results of this study demonstrate that motesanib inhibited thyroid tumor xenograft growth predominantly through inhibition of angiogenesis and possibly via a direct inhibition of VEGFR2 and Ret expressed on tumor cells. These data suggest that targeting angiogenesis pathways and specifically the VEGF pathway may represent a novel therapeutic approach in the treatment of MTC.
Collapse
Affiliation(s)
- A Coxon
- Department of Oncology Research, Amgen Inc., Thousand Oaks, CA 91320, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Freeman DJ, Ogbagabriel S, Bready J, Sun JR, Radinsky R, Hettmann T. Abstract A182: U3–1287 (AMG 888), a fully human anti-HER3 mAb, demonstrates in vitro and in vivo efficacy in the FaDu model of human squamous cell carcinoma of the head and neck (SCCHN). Mol Cancer Ther 2011. [DOI: 10.1158/1535-7163.targ-11-a182] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Anti-EGFR mAbs have demonstrated clinical utility in SCCHN; however, most patients are resistant or acquire resistance to therapy. In preclinical models, activation of HER3 is a resistance mechanism to current HER inhibitors. Recent data (Wilson et al 2011) demonstrated that SCCHN cancer cell lines and primary tumors express both HER3 and heregulin, the ligand for HER3. This autocrine loop is one potential mechanism for the lack of sensitivity to anti-EGFR mAbs observed in SCCNH patients. Herein, we report in vitro and in vivo activity of U3–1287 (AMG 888) as a single agent and in combination with panitumumab, an anti-EGFR mAb, in the FaDu preclinical model of human SCCHN.
Methods: FaDu (SCCHN) cells were treated with U3–1287 (AMG 888), panitumumab, the combination or control mAbs for 4 hours. To determine in vitro efficacy on cell proliferation, FaDu cells were treated with 1 μg/mL U3–1287 (AMG 888), 1 μg/ml panitumumab, the combination or control mAbs in serum containing medium. After 72 hours, the growth of treated cells was measured by ATPLite assay. Levels of pHER3, pEGFR, pERK1/2 and pAKT were measured by Western blot analyzes to determine the inhibition of HER3 oncogenic signaling. To determine in vivo efficacy, mice bearing ∼200 mm3 FaDu xenografts were treated 2×/week with U3–1287 (AMG 888), panitumumab, the combination or control mAbs. Results: Treatment with either U3–1287 (AMG 888) or panitumumab resulted in inhibition of pHER3 and pAKT or pEGFR and pERK1/2, respectively. Treatment with the combination resulted in inhibition of pHER3, pEGFR, pAKT and pERK1/2. Although treatment with panitumumab or U3–1287 (AMG 888) alone significantly inhibited in vitro cell proliferation versus control mAb treated cells (57% (p<0.001) and 38% (p<0.005), respectively), greater inhibition was observed with the combination versus either single agent alone (75% (p<0.01). A dose-dependent inhibition of FaDu xenograft growth was observed with panitumumab or U3–1287 (AMG 888) when used as single agents versus mAb controls (p<0.02 and p<0.01 versus mAb control, respectively). In the combination group (200 μg/ml U3–1287 (AMG 888) and 100 μg/ml panitumumab), treatment resulted in significant tumor inhibition and regressions in all tumors and versus either single agent alone (p<0.0001). To test the durability of the regressions, FaDu xenografts were treated in a separate study with 200 μg/ml U3–1287 (AMG 888) and 100 μg/ml panitumumab again resulting in regressions in all tumors with 8/10 animals remaining tumor free 45 days post the final treatment. Western blot analyzes confirmed a greater inhibition of pHER3 and pAKT in tumors from the combination-treated group versus the single agent-treated groups.
Conclusions: U3–1287 (AMG 888) inhibits proximal and distal HER3 oncogenic signaling in FaDu SCCHN cells resulting in in vitro and in vivo growth inhibition. SCCHN xenografts were sensitive to U3–1287 (AMG 888) treatment as single agent or in combination with panitumumab. Combination treatment with U3–1287 (AMG 888) and panitumumab resulted durable regressions which was not observed with either single agent. These data together with the HER3/heregulin autocrine loop detected in patient samples (Wilson et al 2011) provides evidence for the potential clinical investigation of U3–1287 (AMG 888) in SCCHN.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2011;10(11 Suppl):Abstract nr A182.
Collapse
|
25
|
Ogbagabriel S, Xie J, Juan G, Begley CG, Radinsky R, Freeman DJ. Abstract A150: Molecular mechanisms mediating the pharmacodynamic interactions between oxaliplatin (Ox) and epidermal growth factor receptor (EGFR) inhibitors in KRAS mutant colorectal cancer (CRC) cells. Mol Cancer Ther 2011. [DOI: 10.1158/1535-7163.targ-11-a150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Platinum agents are a standard of care for treatment many cancers. Clinical data has shown that patients (pts) with CRC with mutant (MT) KRAS do not respond to EGFR inhibitors (Amado et al 2009). Furthermore, results from phase 3 clinical trials with erlotinib, cetuximab, or panitumumab have shown that pts whose tumors express MT KRAS have shorter progression-free survival and overall survival when an EGFR inhibitor is added to a platinum-containing regimen vs chemotherapy alone (Eberhard et al 2005, Bokemeyer et al 2011, Douillard et al 2010). However, KRAS status is not predictive of outcomes in pts receiving Ox- or irinotecan-containing regimens without an EGFR inhibitor (Richman et al 2009). This negative interaction has not been observed in pts whose tumors express either wild type (WT) KRAS receiving an EGFR inhibitor and chemotherapy or whose tumors express MT KRAS receiving an EGFR inhibitor with irinotecan (Peeters et al 2010, Van Cutsem et al 2009). Our goal was to gain a molecular mechanistic understanding of the negative interaction between EGFR inhibitors and Ox in KRAS MT CRC cells.
Methods: To investigate the negative interaction between Ox and EGFR inhibitors, isogenic MT and WT KRAS-expressing HCT116 CRC cells were treated with Ox, SN-38 (the active metabolite of irinotecan), panitumumab, or gefitinib as single agents or in combination for 72 hrs. Viability was measured using an ATPlite assay. To determine the cellular distribution of EGFR, cells were serum-starved, labeled with a fluorescent anti-EGFR mAb, and visualized by a confocal microscopy. To analyze the effects of single agent or combination treatment on downstream phosphorylation of the PI3K or MAPK pathways, cells were treated for 24 hrs and phospho-proteins were detected by Western blotting. To investigate whether negative interaction between Ox and EGFR inhibitors could be reversed, cells were treated with Ox and gefitinib in combination with inhibitors to MEK, PI3K or Src for 72 hrs.
Results: Treatment with gefitinib, but not panitumumab, reversed the anti-proliferative effects of Ox in the MT KRAS-expressing CRC cells vs Ox alone (p<0.0005). Neither treatment reversed the anti-proliferative effects of Ox observed in the WT KRAS-expressing cells or SN-38 in either the MT or WT KRAS-expressing cells. In the MT KRAS-expressing cells, EGFR was predominantly expressed intracellularly; in contrast, distinct cell surface staining was observed in the W T-KRAS expressing cells. This difference correlated with the inability of panitumumab to reverse the anti-proliferative effects of Ox in the CRC cells. Combination treatment of MT KRAS CRC cells with Ox and gefitinib increased pAKT which was not observed with Ox alone. Treatment of the mutant KRAS-expressing cells with a MEK, PI3K or Src inhibitor reversed the negative interaction between Ox and gefitinib (p<0.0005).
Conclusion: We developed a preclinical model to further understand the negative interaction between MT KRAS-expressing cancer cells, platinum agents, and EGFR inhibitors. Feedback though AKT may contribute to the increased resistance to Ox in KRAS MT cells. Inhibitors of MEK, PI3K, or Src reversed the negative interaction between the EGFR inhibitors and Ox in a mutant-KRAS genetic background.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2011;10(11 Suppl):Abstract nr A150.
Collapse
|
26
|
Pollock RE, Lang A, El-Naggar AK, Radinsky R, Hung MC. Enhanced MDM2 Oncoprotein Expression in Soft Tissue Sarcoma: Several Possible Regulatory Mechanisms. Sarcoma 2011; 1:23-9. [PMID: 18521197 PMCID: PMC2373579 DOI: 10.1080/13577149778443] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
Purpose. MDM2 is an oncogene whose protein product may promote tumorigenesis by blocking
wild-type p53 tumor suppressor mediated G 0/G1 cell cycle arrest, thereby inhibiting repair of damaged DNA prior to cell division. While
MDM2 DNA amplification is frequently observed in human sarcoma, the mechanisms linking this amplification to MDM2
oncoprotein over-production as well as its functional significance have not been well characterized in patients with soft
tissue sarcoma. Methods. A tissue bank of resected soft tissue sarcomas and autologous normal tissues was assembled; all specimens were
snap frozen within 15 min of resection. DNA and RNA were extracted from tissues using isoamyl alcohol and phenol
chloroform extraction methods, respectively; cell lysates were prepared using PBSTDS lysis buffer. DNA and mRNA were
confirmed as being non-degraded and were then examined for MDM2 DNA amplification (Southern blots) and mRNA
over-expression (Northern blots) using actin (DNA) and glyceraldehyde-3-phosphate dehydrogenase (mRNA) as loading
controls. The MDM2 protein was examined on Western blots using the MDM2-specific monoclonal antibody IF2
(Oncogene Science, Inc). The presence of p53 DNA and expression of p53 mRNA was examined by rehybridizing the
Southern and Northern filters using a p53-specific cDNA probe. Results. Soft tissue sarcomas and autologous normal tissues were screened for MDM2 DNA amplification, which was
detected in 10 of 30 tumors screened. After screening, there was sufficient biomaterials from six specimens for subsequent
Northern and Western analysis to see whether MDM2 gene amplification correlated with over-expression of MDM2
mRNA and MDM2 protein. In addition, we examined whether other mechanisms may lead to over-expression of the
MDM2 oncoprotein. Several possible mechanisms of MDM2 oncoprotein over-expression were identified. These most
commonly included MDM2 DNA amplification, MDM2 mRNA over-expression and MDM2 oncoprotein over-expression.
However, some soft tissue sarcoma patient specimens had no evidence of MDM2 mRNA over-expression yet had
MDM2 oncoprotein over-production in the tumor relative to autologous normal tissue, implying possible post-transcriptional
regulation. Of functional relevance, MDM2 oncoprotein over-production by tumors was associated with large
decreases in the percentage of cells in the
0/G1 cell cycle interface compared with autologous normal tissue cells. Discussion. It is likely that there are multiple mechanisms underlying human soft tissue sarcoma MDM2 oncoprotein
over-production. Consequently, strategies that decrease MDM2 over-production, such as transcriptional repression to
inhibit MDM2 promoter activity or RNA antisense approaches, may ultimately offer the best therapeutic efficacy.
Collapse
Affiliation(s)
- R E Pollock
- Department of Surgical Oncology MD Anderson Cancer Center 1515 Holcombe Blvd, Box 106 University of Texas Houston TX 77030 USA
| | | | | | | | | |
Collapse
|
27
|
Rossin R, Kohno T, Hagooly A, Sharp T, Gliniak B, Arroll T, Chen Q, Hewig A, Kaplan-Lefko P, Friberg G, Radinsky R, Evelhoch JL, Welch MJ, Hwang DR. Characterization of 64Cu-DOTA-Conatumumab: A PET Tracer for In Vivo Imaging of Death Receptor 5. J Nucl Med 2011; 52:942-9. [DOI: 10.2967/jnumed.110.086157] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
28
|
Bush TL, Heller S, Chung G, Guyot D, Kendall R, Friberg G, Radinsky R, Payton M. Abstract 3556: Antitumor activity of AMG 900, an orally available small molecule inhibitor of aurora kinases, alone and in combination with tubulin-targeting agents in human metastatic breast cancer. Cancer Res 2011. [DOI: 10.1158/1538-7445.am2011-3556] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Breast cancer is a heterogeneous disease that can be classified into distinct subtypes. The breast cancer subtype that lacks expression of hormone receptors (ER and PR) is characterized by its aggressive and metastatic nature. Tubulin-targeting agents are among the most active agents for the treatment of metastatic breast cancer (MBC). However, treatment of MBC frequently fails because of de novo or acquired resistance to taxanes. Consequently, there is an urgent need for novel therapeutics and combination strategies to effectively treat multidrug-resistant MBC. Recently, we reported the development of AMG 900, a novel ATP competitive small molecule inhibitor that is potent and selective for aurora-A, -B, and -C kinases. AMG 900 inhibits the proliferation of tumor cell lines and growth of multiple human xenografts, including taxane-resistant models. AMG 900 is currently in early clinical testing in advanced cancers.
Objective: To evaluate the effectiveness of AMG 900 alone and in combination with two different classes of tubulin-targeting agents (taxanes and epothilones) in human MDA-MB-231 (parental and taxane-resistant subline) MBC cell lines and xenografts.
Results: The MDA-MB-231 parental cell line is tumorigenic and metastatic in vivo. To establish the taxane-resistant cell line, MDA-MB-231-PTX-r, MDA-MB-231 parental cells were adapted to grow in the presence of increasing concentrations of paclitaxel. In vitro, AMG 900 induced polyploidy and inhibited colony growth of both MDA-MB-231 and MDA-MB-231-PTX-r cell lines. In combination, AMG 900 enhanced the effects of both paclitaxel and ixabepilone in a cell growth assay using MDA-MB-231 and MDA-MB-231-PTX-r cell lines, respectively. In tumor-bearing mice, AMG 900 blocked the phosphorylation of histone H3 and significantly inhibited the growth of both MDA-MB-231 and MDA-MB-231-PTX-r xenografts (>70% inhibition; p < 0.0002). To examine the effects of AMG 900 in combination with tubulin-targeting agents, mice were administered either docetaxel or ixabepilone (day 1) followed by AMG 900 (day 2 and 3). AMG 900 plus docetaxel resulted in enhanced efficacy in the MDA-MB-231 xenografts compared to either single agent (p < 0.0006). Notably, AMG 900 plus ixabepilone resulted in tumor regressions in the MDA-MB-231-PTX-r xenografts compared to either single agent (p < 0.0001). Histological analysis of the MDA-MB-231-PTX-r tumors revealed a pronounced increase in multinucleated cells after combined treatment with AMG 900 and ixabepilone compared to either single agent.
Conclusion: AMG 900, alone or in combination with tubulin-targeting agents such as ixabepilone, has the potential to treat multidrug resistant metastatic breast cancer.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3556. doi:10.1158/1538-7445.AM2011-3556
Collapse
|
29
|
Coxon A, Bready J, Min H, Kaufman S, Leal J, Yu D, Lee TA, Sun JR, Estrada J, Bolon B, McCabe J, Wang L, Rex K, Caenepeel S, Hughes P, Cordover D, Kim H, Han SJ, Michaels ML, Hsu E, Shimamoto G, Cattley R, Hurh E, Nguyen L, Wang SX, Ndifor A, Hayward IJ, Falcón BL, McDonald DM, Li L, Boone T, Kendall R, Radinsky R, Oliner JD. Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody. Mol Cancer Ther 2011; 9:2641-51. [PMID: 20937592 DOI: 10.1158/1535-7163.mct-10-0213] [Citation(s) in RCA: 131] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
AMG 386 is an investigational first-in-class peptide-Fc fusion protein (peptibody) that inhibits angiogenesis by preventing the interaction of angiopoietin-1 (Ang1) and Ang2 with their receptor, Tie2. Although the therapeutic value of blocking Ang2 has been shown in several models of tumorigenesis and angiogenesis, the potential benefit of Ang1 antagonism is less clear. To investigate the consequences of Ang1 neutralization, we have developed potent and selective peptibodies that inhibit the interaction between Ang1 and its receptor, Tie2. Although selective Ang1 antagonism has no independent effect in models of angiogenesis-associated diseases (cancer and diabetic retinopathy), it induces ovarian atrophy in normal juvenile rats and inhibits ovarian follicular angiogenesis in a hormone-induced ovulation model. Surprisingly, the activity of Ang1 inhibitors seems to be unmasked in some disease models when combined with Ang2 inhibitors, even in the context of concurrent vascular endothelial growth factor inhibition. Dual inhibition of Ang1 and Ang2 using AMG 386 or a combination of Ang1- and Ang2-selective peptibodies cooperatively suppresses tumor xenograft growth and ovarian follicular angiogenesis; however, Ang1 inhibition fails to augment the suppressive effect of Ang2 inhibition on tumor endothelial cell proliferation, corneal angiogenesis, and oxygen-induced retinal angiogenesis. In no case was Ang1 inhibition shown to (a) confer superior activity to Ang2 inhibition or dual Ang1/2 inhibition or (b) antagonize the efficacy of Ang2 inhibition. These results imply that Ang1 plays a context-dependent role in promoting postnatal angiogenesis and that dual Ang1/2 inhibition is superior to selective Ang2 inhibition for suppression of angiogenesis in some postnatal settings.
Collapse
Affiliation(s)
- Angela Coxon
- Department of Oncology Research, Amgen, Inc., Thousand Oaks, California 91320, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Beltran PJ, Chung YA, Moody G, Mitchell P, Cajulis E, Vonderfecht S, Kendall R, Radinsky R, Calzone FJ. Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models. J Pharmacol Exp Ther 2011; 337:644-54. [PMID: 21385891 DOI: 10.1124/jpet.110.178400] [Citation(s) in RCA: 60] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Ewing's and osteogenic sarcoma are two of the leading causes of cancer deaths in children and adolescents. Recent data suggest that sarcomas may depend on the insulin-like growth factor type 1 (IGF-1) receptor (IGF1R) and/or the insulin receptor (INSR) to drive tumor growth, survival, and resistance to mammalian target of rapamycin complex 1 (mTORC1) inhibitors. We evaluated the therapeutic value of ganitumab (AMG 479; C(6472)H(10028)N(1728)O(2020)S(42)), an anti-IGF1R, fully human monoclonal antibody, alone and in combination with rapamycin (mTORC1 inhibitor) in Ewing's (SK-ES-1 and A673) and osteogenic (SJSA-1) sarcoma models. IGF1R was activated by IGF-1 but not by insulin in each sarcoma model. INSR was also activated by IGF-1 in the SJSA-1 and SK-ES-1 models, but not in the A673 model where insulin was the preferred INSR ligand. Ganitumab significantly inhibited the growth of SJSA-1 and SK-ES-1 xenografts; inhibition was associated with decreased IGF1R and Akt phosphorylation, reduced total IGF1R and bromodeoxyuridine detection, and increased caspase-3 expression. Ganitumab inhibited rapamycin-induced IGF1R, Akt, and glycogen synthase kinase-3β hyperphosphorylation in each sarcoma model. However, ganitumab in combination with rapamycin also resulted in a marked increase in INSR expression and activity in the SJSA-1 and A673 models. The in vivo efficacy of ganitumab in the two ganitumab-sensitive models (SJSA-1 and SK-ES-1) was significantly enhanced in combination with rapamycin. Our results support studying ganitumab in combination with mTORC1 inhibitors for the treatment of sarcomas and suggest that INSR signaling is an important mechanism of resistance to IGF1R blockade.
Collapse
Affiliation(s)
- Pedro J Beltran
- Oncology Research Therapeutic Area, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Payton M, Bush TL, Chung G, Ziegler B, Eden P, McElroy P, Ross S, Cee VJ, Deak HL, Hodous BL, Nguyen HN, Olivieri PR, Romero K, Schenkel LB, Bak A, Stanton M, Dussault I, Patel VF, Geuns-Meyer S, Radinsky R, Kendall RL. Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. Cancer Res 2010; 70:9846-54. [PMID: 20935223 DOI: 10.1158/0008-5472.can-10-3001] [Citation(s) in RCA: 97] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
In mammalian cells, the aurora kinases (aurora-A, -B, and -C) play essential roles in regulating cell division. The expression of aurora-A and -B is elevated in a variety of human cancers and is associated with high proliferation rates and poor prognosis, making them attractive targets for anticancer therapy. AMG 900 is an orally bioavailable, potent, and highly selective pan-aurora kinase inhibitor that is active in taxane-resistant tumor cell lines. In tumor cells, AMG 900 inhibited autophosphorylation of aurora-A and -B as well as phosphorylation of histone H3 on Ser(10), a proximal substrate of aurora-B. The predominant cellular response of tumor cells to AMG 900 treatment was aborted cell division without a prolonged mitotic arrest, which ultimately resulted in cell death. AMG 900 inhibited the proliferation of 26 tumor cell lines, including cell lines resistant to the antimitotic drug paclitaxel and to other aurora kinase inhibitors (AZD1152, MK-0457, and PHA-739358), at low nanomolar concentrations. Furthermore, AMG 900 was active in an AZD1152-resistant HCT116 variant cell line that harbors an aurora-B mutation (W221L). Oral administration of AMG 900 blocked the phosphorylation of histone H3 in a dose-dependent manner and significantly inhibited the growth of HCT116 tumor xenografts. Importantly, AMG 900 was broadly active in multiple xenograft models, including 3 multidrug-resistant xenograft models, representing 5 tumor types. AMG 900 has entered clinical evaluation in adult patients with advanced cancers and has the potential to treat tumors refractory to anticancer drugs such as the taxanes.
Collapse
Affiliation(s)
- Marc Payton
- Department of Oncology Research, Amgen Inc., Thousand Oaks, California 91320, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Cee VJ, Schenkel LB, Hodous BL, Deak HL, Nguyen HN, Olivieri PR, Romero K, Bak A, Be X, Bellon S, Bush TL, Cheng AC, Chung G, Coats S, Eden PM, Hanestad K, Gallant PL, Gu Y, Huang X, Kendall RL, Lin MHJ, Morrison MJ, Patel VF, Radinsky R, Rose PE, Ross S, Sun JR, Tang J, Zhao H, Payton M, Geuns-Meyer SD. Discovery of a Potent, Selective, and Orally Bioavailable Pyridinyl-Pyrimidine Phthalazine Aurora Kinase Inhibitor. J Med Chem 2010; 53:6368-77. [DOI: 10.1021/jm100394y] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Affiliation(s)
| | | | | | | | | | | | | | | | - Xuhai Be
- Pharmacokinetics and Drug Metabolism
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Carnahan J, Beltran PJ, Babij C, Le Q, Rose MJ, Vonderfecht S, Kim JL, Smith AL, Nagapudi K, Broome MA, Fernando M, Kha H, Belmontes B, Radinsky R, Kendall R, Burgess TL. Selective and potent Raf inhibitors paradoxically stimulate normal cell proliferation and tumor growth. Mol Cancer Ther 2010; 9:2399-410. [PMID: 20663930 DOI: 10.1158/1535-7163.mct-10-0181] [Citation(s) in RCA: 67] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Raf inhibitors are under clinical investigation, specifically in patients with tumor types harboring frequent activating mutations in B-Raf. Here, we show that cell lines and tumors harboring mutant B-Raf were sensitive to a novel series of Raf inhibitors (e.g., (V600E)B-Raf A375, IC(50) on cells = 2 nmol/L; ED(50) on tumor xenografts = 1.3 mg/kg). However, in cells and tumors with wild-type B-Raf, exposure to Raf inhibitors resulted in a dose-dependent and sustained activation of mitogen-activated protein kinase signaling. In some of these cell lines, Raf inhibition led to entry into the cell cycle, enhanced proliferation, and significantly stimulated tumor growth in vivo. Inhibition with structurally distinct Raf inhibitors or isoform-specific small interfering RNA knockdown of Raf showed that these effects were mediated directly through Raf. Either A-Raf or C-Raf mediated the Raf inhibitor-induced mitogen-activated protein kinase pathway activation in an inhibitor-specific manner. These paradoxical effects of Raf inhibition were seen in malignant and normal cells in vitro and in vivo. Hyperplasia of normal epithelial cells in the esophagus and the stomach was evident in mice with all efficacious Raf inhibitors (n = 8) tested. An implication of these results is that Raf inhibitors may induce unexpected normal cell and tumor tissue proliferation in patients.
Collapse
Affiliation(s)
- Josette Carnahan
- Department of Hematology, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Canon J, Bryant R, Roudier M, Osgood T, Jones J, Miller R, Coxon A, Radinsky R, Dougall WC. Inhibition of RANKL increases the anti-tumor effect of the EGFR inhibitor panitumumab in a murine model of bone metastasis. Bone 2010; 46:1613-9. [PMID: 20215062 DOI: 10.1016/j.bone.2010.03.001] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/20/2009] [Accepted: 03/01/2010] [Indexed: 12/31/2022]
Abstract
Bone metastases cause severe skeletal complications and are associated with osteoclast-mediated bone destruction. RANKL is essential for osteoclast formation, function, and survival, and is the primary effector of tumor-induced osteoclastogenesis and osteolysis. RANKL inhibition by its soluble decoy receptor osteoprotegerin (OPG) prevents tumor-induced osteolysis and decreases skeletal tumor burden. Because osteoclast-mediated bone resorption releases growth factors from the bone matrix, the host bone microenvironment induces a vicious cycle of bone destruction and tumor proliferation and survival. A prediction of this vicious cycle hypothesis is that targeting the host bone microenvironment by osteoclast inhibition would reduce tumor growth and survival and may enhance the anti-tumor effects of targeted therapies. The epidermal growth factor receptor (EGFR) pathway regulates critical processes such as cell growth and survival, and anti-EGFR therapies can cause tumor cell arrest and apoptosis. We evaluated whether reduction of osteolysis by RANKL inhibition could enhance the anti-tumor effects of an anti-EGFR antibody (panitumumab) in a novel murine model of human A431 epidermoid carcinoma bone metastasis. Skeletal tumor progression was assessed longitudinally by bioluminescence imaging. RANKL inhibition by OPG-Fc treatment resulted in a reduction in tumor progression in bony sites. OPG-Fc treatment also caused a dose-dependent reduction in tumor-induced osteolysis, supporting the essential role of RANKL in this process. In combination, RANKL inhibition increased the anti-tumor efficacy of an anti-EGFR antibody, and completely blocked tumor-induced bone breakdown, demonstrating that addition of the indirect anti-tumor effect of RANKL inhibition increases the anti-tumor efficacy of panitumumab, a targeted anti-EGFR antibody.
Collapse
Affiliation(s)
- Jude Canon
- Department of Oncology Research, Amgen Inc., Thousand Oaks, CA, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Geuns-Meyer S, Cee VJ, Deak HL, Du B, Hodous BL, Nguyen HN, Olivieri PR, Romero K, Schenkel LB, Patel VF, Be X, Bush TL, Chung G, Eden P, Huang L, Kendall R, Lin MHJ, Radinsky R, Ziegler B, Payton M. Abstract 5776: Discovery of AMG 900, a highly selective, orally bioavailable inhibitor of aurora kinases with efficacy in preclinical antitumor models and activity against multidrug-resistant cells. Cancer Res 2010. [DOI: 10.1158/1538-7445.am10-5776] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The aurora family of serine/threonine kinases (Aurora-A, -B, -C) regulate cell-cycle progression in mammalian cells. Whereas aurora kinase C function appears restricted to meiosis in males, aurora kinases A and B are essential for proper chromosome congression, segregation, and cytokinesis during mitosis. Aurora kinases A and B have been implicated in tumorigenesis, with overexpression levels correlating to clinical staging of cancers and poor prognosis. Thus, these mitotic kinases have become the subject of much interest as targets for anticancer therapy.
N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-phenyl-1-phthalazinamine was a key aurora kinase inhibitor lead, possessing oral bioavailability in rats that was lacking in the anthranilamide compounds from which it was derived. This phthalazine compound possessed a key feature that was deemed important to maintain in a clinical candidate: potency against a model multidrug resistant (MDR) cell line (MES-SA Dx5) commensurate with its activity against a cell line that does not overexpress P-gp (HeLa). Improved in vivo potency was desired, as measured by suppression of the phosphorylation of the aurora kinase B substrate Histone H3 on Ser10 six hours after dosing. SAR from targeting this improvement in in vivo activity uncovered a delicate balance between protein binding, pharmacokinetic parameters, and cell potency in MES-SA Dx5 cells. AMG 900 was identified as a suitable candidate for clinical development based on its low single digit nanomolar potency against MDR cell lines, robust PD response (with complete suppression of Histone H3 phosphorylation at six hours), and high selectivity against other kinases. Oral administration of AMG 900 at a well-tolerated dose of 4 mg/kg BID inhibited tumor growth (83% TGI; p < 0.0001) in an HCT116 xenograft model. AMG 900 is currently undergoing phase 1 clinical evaluation in patients with advanced solid tumors.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 5776.
Collapse
|
36
|
Bush TL, Chung G, Ziegler B, Eden P, McElroy P, Lin MHJ, Radinsky R, Kendall R, Geuns-Meyer S, Payton M. Abstract 4437: Preclinical characterization of AMG 900, an orally available small molecule inhibitor of aurora kinases in phase 1 clinical trials. Cancer Res 2010. [DOI: 10.1158/1538-7445.am10-4437] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The aurora family of serine-threonine kinases (aurora-A, -B, -C) regulate cell-cycle progression in mammalian cells. Aurora-A and aurora-B are essential for proper chromosome congression, segregation, and cytokinesis during mitosis, whereas aurora-C function appears restricted to male meiosis. Aurora-B is responsible for the direct phosphorylation of histone H3 on serine-10. Aurora-A and aurora-B expression is elevated in a variety of human cancers and is associated with advanced clinical staging and poor prognosis. The emergence of aurora kinases as key mitotic regulators and their potential role in tumorigenesis has focused substantial interest in developing selective small molecule inhibitors for the treatment of human cancers.
Objective: The aim of this study was to determine the in vitro effects of AMG 900 on a panel of tumor cell lines and profiling its antitumor activity across multiple human xenograft models.
Results: AMG 900 is a novel ATP competitive small molecule inhibitor that is potent and highly selective for aurora kinases A, B, and C. In cells, AMG 900 inhibits autophosphorylation of aurora-A and aurora-B as well as the phosphorylation of histone H3. The predominant cellular response of tumor cells to AMG 900 treatment is aborted cell division, which leads to endoreduplication and cell death. The effect of AMG 900 was tested in a panel of 26 cell lines to evaluate its potential to inhibit cell proliferation across multiple tumor types. AMG 900 inhibited the proliferation of tumor cell lines at low nanomolar concentrations (EC50 values 1-6 nM), including a number of multidrug resistant (MDR) cell lines expressing ATP-binding cassette transporters (P-gp and BCRP1). In contrast, paclitaxel and three aurora kinase inhibitors (AZD1152, MK-0457, and PHA-739358) showed a loss of potency in these MDR cell lines compared to matched parental cell lines. In nude mice, oral administration of AMG 900 inhibited phosphorylation of histone H3 in tumors in a concentration- and dose-dependent manner. The effect of AMG 900 was tested in a panel of nine human xenografts representing five tumor types (breast, colon, lung, pancreatic, and uterine). Oral administration of AMG 900 at 15 mg/kg BID for two consecutive days per week or 3 mg/kg BID every day inhibited tumor growth (50-97%, P < 0.005) in all nine of the xenograft models. Importantly, three of these xenograft models are resistant to taxanes. Mice treated with efficacious doses of AMG 900 showed a transient loss of body weight and bone marrow cellularity, consistent with its on-mechanism effects on normal proliferating cells.
Conclusion: Based on these preclinical activities, AMG 900 has the potential to treat advanced cancers, including tumors resistant to chemotherapeutic agents such as paclitaxel and docetaxel. AMG 900 is currently undergoing phase 1 clinical evaluation in patients with advanced solid tumors.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 4437.
Collapse
|
37
|
Beltran PJ, Carnahan J, Le Q, Fernando M, Rose MJ, Nagapudi K, Smith AL, Kim JL, Belmontes B, Burgess TL, Kendall R, Radinsky R. Abstract 2519: Efficacy of a potent and selective Raf inhibitor against human xenograft models displaying specific genetic mutations in the MAPK signaling pathway. Cancer Res 2010. [DOI: 10.1158/1538-7445.am10-2519] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: A significant percentage of human melanomas as well as colon, ovarian and thyroid carcinomas display missense mutations in B-Raf which can drive cellular transformation through constitutive activation of the MAPK signaling pathway. Thus, mutant B-Raf represents an attractive target to develop new oncology therapeutics. Here we describe the in vivo potency and efficacy of a novel Raf inhibitor (cmpd 1) against xenograft models displaying mutations in the MAPK signaling pathway.
Methods: Established human xenograft models implanted in athymic female nude mice were used to examine the effects of cmpd 1 on P-ERK basal level and tumor growth. For examination of pharmacodynamic effect, cmpd 1 was dosed orally, once for 6-8 hours prior to collection of the xenograft and peripheral blood. Collected xenografts were lysed and levels of P-ERK analyzed by Meso Scale Detection Assay (MSD). Plasma concentrations of cmpd 1 were determined using Quantitative Liquid Chromatography-Tandem Mass Spectometry (LC-MS/MS). In order to study the effects of cmpd 1 on tumor growth inhibition (TGI), mice with established xenografts (∼ 200-250 cubic mm) were randomized into 4 groups (n=10) on day 0. Mice were dosed orally, once (QD) or twice (BID) per day starting on day 1 until completion of the experiment. Tumor volume and body weight were measured twice per week. Significant TGI was determined using repeated measures ANOVA (RMANOVA) followed by the Dunnett's test.
Results: Models expressing B-Raf activating mutations (A375, WM-266 and Colo-205) showed significant decreased expression of P-ERK (>70%) and significant TGI, including complete stasis (100% TGI) and regression at 5 mg/kg QD (ED50 1-3 mg/kg). Models with activating NRAS mutations also showed sensitivity to cmpd 1 but higher doses were required to achieve significant reduction of P-ERK level and tumor growth inhibition (ED50 11 mg/kg). Models with activating KRAS mutations displayed responses ranging from stimulation of tumor growth (MiaPaCa-2) to lack of effect (A549) or 40% TGI (HCT-116). These suboptimal responses in KRAS mutant models were observed even when cmpd 1 was dosed at 10 mg/kg BID. Finally, BxPC-3, a xenograft model with a wild-type (WT) MAPK signaling pathway, displayed sensitivity to cmpd 1 albeit to a lesser extend than observed in B-Raf mutant models (ED50 6.0 mg/kg). In most models, TGI was directly correlated to the ability of cmpd 1 to reduce P-ERK levels in vivo. Plasma exposures of cmpd 1 were approximately proportional to the administered dose.
Conclusion: These results show that inhibition of P-ERK by this Raf inhibitor can result in significant TGI in mutant B-Raf, NRAS and WT models while significant sensitivity can be lost in KRAS mutant models. In addition, the data also show that under certain circumstances, the inhibition of Raf in KRAS mutant cell lines can result in stimulation of tumor growth.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2519.
Collapse
|
38
|
Hettmann T, Schneider M, Ogbagabriel S, Xie J, Juan G, Hartmann S, Radinsky R, Freeman DJ. Abstract LB-306: U3-1287 (AMG 888), a fully human anti-HER3 mAb, inhibits HER3 activation and induces HER3 internalization and degradation. Cancer Res 2010. [DOI: 10.1158/1538-7445.am10-lb-306] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Understanding the mechanism of action (MOA) of novel therapeutic agents is instrumental for their recommended use in the clinic. U3-1287 (AMG 888) is a novel, fully human mAb that targets HER3, a member of the EGFR family involved in tumor growth and resistance to anti-HER inhibitors. To understand its MOA, we evaluated HER3 internalization, degradation, and downstream signaling in tumor cell lines in response to U3-1287 (AMG 888) treatment.
Methods: Confocal microscopy was used to locate antibody/receptor complexes. MDA-MB-453 and MDA-MB-175 breast cancer cells were serum starved overnight and treated on ice with 10 ug/mL of quantum dot 585 (Invitrogen) conjugated U3-1287 (AMG 888) and 2 ug/mL of quantum dot 655 (Invitrogen) conjugated HER2 Ab5 (Labvision). Images were taken at time 0 and after 1 hour incubation at 37°C. In addition, cell surface reduction of HER3 was measured by flow cytometry. T47D breast cancer cells were incubated at 37°C for 0, 1, 4 and 24 hours with either U3-1287 (AMG 888), c225, trastuzumab or c2C4 (10 µg/ml). The cells were re-stained with the same primary antibodies (10 µg/ml) at 4°C, and analyzed. To evaluate the consequence of longer term U3-1287 (AMG 888) treatment, BxPC3 pancreatic cells were treated from 0-96 hours in vitro and A549 NSCLC xenografts were treated for 2 weeks in vivo. Total HER3, pHER3 and pAKT were measured by Western blot and HER3 mRNA was measured by RT-PCR.
Results: U3-1287 (AMG 888) treatment of MDA-MB-453 and MDA-MB-175 cells resulted in the internalization of HER3 but not HER2. Treatment of T47D cells with trastuzumab, c2C4 or c225, U3-1287 (AMG 888) resulted in a 8, 4, 0 and 73% reduction of cell surface HER2, HER2, HER1 and HER3, respectively at the 1 hr time point. A ∼75% reduction of HER3 was maintained during the 24 hr treatment with U3-1287 (AMG 888). Although a 60% reduction in total HER3 was not observed until 4 hours post treatment of BxPC3 cells with U3-1287 (AMG 888), pHER3 and pAKT were reduced >90% within 15 minutes. Neither U3-1287 (AMG 888) nor heregulin (the ligand for HER3) treatment resulted in a significant change in HER3 mRNA levels over the 96 hr treatment period. Analyses of A549 tumor xenograft tissue demonstrated a dose dependent loss of total HER3 and pHER3 in response to U3-1287 (AMG 888) administration versus IgG control treatment.
Conclusions: We demonstrate that U3-1287 (AMG 888)-induced inhibition of HER3 signaling and HER3 degradation are separate events, whereby loss of HER3 receptor in response to U3-1287 (AMG 888) treatment is preceded by U3-1287 (AMG 888)-mediated inhibition of HER3 activation. HER3 transcription is not affected by U3-1287 (AMG 888) or heregulin in BxPC3 cells. These findings suggest that U3-1287 (AMG 888) mediates both inhibition of HER3 downstream signaling and HER3 degradation and that these mechanisms may contribute to the activity of U3-1287 (AMG 888) in the clinic.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr LB-306.
Collapse
|
39
|
Ziegler B, Juan G, Chung G, Manoukian R, Huang L, Lin MHJ, Ma C, Zoog S, Geuns-Meyer S, Kendall R, Radinsky R, Friberg G, Payton M, Bush TL. Abstract 3600: Preclinical pharmacokinetic and biomarker analysis of AMG 900, an orally available small molecule inhibitor of aurora kinases, in human xenograft tumor and surrogate tissues. Cancer Res 2010. [DOI: 10.1158/1538-7445.am10-3600] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The aurora family of serine-threonine kinases (Aurora-A, -B, -C) regulate cell-cycle progression in mammalian cells. Aurora kinases A and B are essential for proper chromosome congression, segregation, and cytokinesis during mitosis, whereas aurora kinase C function appears restricted to male meiosis. Aurora kinase B is responsible for the direct phosphorylation of histone H3 on serine-10 (p-histone H3). Aurora kinase A and B expression is elevated in a variety of human cancers and is associated with advanced clinical staging and poor prognosis. With the emergence of aurora kinases as key mitotic regulators and their potential role in tumorigenesis, we developed AMG 900, a novel ATP competitive small molecule inhibitor, that is highly potent and selective for aurora kinases A, B, and C. In vivo, AMG 900 inhibits the growth of multiple human tumor xenografts, including multidrug-resistant models.
Objective: The aim of this study was to establish a pharmacokinetic-pharmacodynamic (PK-PD) relationship for AMG 900 in human tumor xenografts and surrogate tissues.
Results: In nude mice, oral administration of AMG 900 inhibited p-histone H3 in tumors and bone marrow in a concentration- and dose-dependent manner. To further refine the AMG 900 PK-PD relationship, p-histone H3 IC50 values for bone marrow and dissociated COLO 205 tumors from mice were associated with plasma concentrations of 294 and 273 ng/mL, respectively. The duration of target coverage required for anti-tumor efficacy was determined to be > 6 hours per day above the in vivo p-histone H3 IC50 using different dosing schedules. To explore whether skin could be a suitable surrogate tissue for measuring p-histone H3 inhibition, tumor-bearing mice were administered AMG 900 at 3.75, 7.5, and 15 mg/kg for 3 hours. Significant suppression of p-histone H3 in skin was only observed at 15 mg/kg (p < 0.0001), whereas in tumor, a dose-dependent inhibition was achieved at all doses (p < 0.0015). To determine the feasibility of measuring p-histone H3 using fine-needle aspirate (FNA) tumor biopsies, tumor-bearing mice were administered AMG 900 at 15 mg/kg for 3 hours. Treatment with AMG 900 significantly inhibited p-histone H3 (> 99%, p < 0.0001) in COLO 205 tumors, suggesting that FNA biopsies may be a viable approach for assessing AMG 900 PD effects in the clinic.
Conclusion: These studies demonstrate that AMG 900 inhibits p-histone H3 in tumors and surrogate tissues, although tissues such as skin may be less sensitive to assess PD effects. The use of p-histone H3 as a biomarker to determine plasma levels of AMG 900 required to inhibit aurora B activity may be useful in clinical studies.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3600.
Collapse
|
40
|
Hettman T, Schneider M, Blum S, Hartmann S, Hendrich M, Moor R, Ogbagabriel S, Radinsky R, Freeman D. Abstract B161: U3-1287 (AMG 888), a fully human anti-HER3 mAb, demonstrates preclinical efficacy in HER2+ and HER2− breast cancer models. Mol Cancer Ther 2009. [DOI: 10.1158/1535-7163.targ-09-b161] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: HER3 is required for proliferation in HER2 amplified (HER2+) breast cancer cell lines, but may also be important in the HER2 negative (HER2−) setting. Though HER3 lacks kinase activity, it is a scaffold for PI3K signaling for the HER family and other receptor kinases via heterodimeric interactions. In preclinical models, activation of HER3 is a resistance mechanism to current HER family inhibitors. We report the efficacy of U3-1287 (AMG 888) in HER2+ and HER2− preclinical breast cancer models. We also evaluate human breast tumor samples for detectable levels of pHER3 and pAKT.
Methods: Levels of pHER3, pERK and pAKT were determined by western blotting. To determine the inhibition of HER3 oncogenic signaling, HER2+ (SKBR3, MDA-MB-453 and HCC1569) and HER2− (MDA-MB-175 VII) breast cancer cells were treated with 10 µg/ml of U3-1287 (AMG 888), cetuximab, c2C4, trastuzumab, lapatinib (250 to 1500 nM) or controls prior to heregulin (HRG) stimulation. To determine the activity on cell proliferation in the presence of 0.4% FBS, breast cancer cell lines were incubated with 10 µg/ml of U3-1287 (AMG 888), cetuximab, c2C4, trastuzumab, lapatinib (50 to 1500 nM) or control for 1 hour prior to HRG stimulation. After 4 days, the growth of treated cells was measured with alamarBlue™. To determine the activity on anchorage-independent growth, breast cancer cells were treated with 2 to 5 g/ml U3-1287 (AMG 888), anti-HER antibodies, 500 nM lapatinib, or control. Tumor cell colonies formed in the absence or presence of HRG for 6 to 10 days and were stained with MTT for 4 to 6 hours and quantified.
Results: Treatment of breast cancer cell lines with U3-1287 (AMG 888) resulted in an inhibition of pHER3 and pAKT. In cell proliferation assays, U3- 1287 (AMG 888) reduced heregulin-stimulated SkBR-3 proliferation up to 40% (p<0.05) as a single agent, and up to 80% (p<0.05) when combined with other HER inhibitors. Additive activity was observed in MDA-MB 175 VII cells when U3-1287 (AMG 888) was combined with standard of care chemotherapeutics (gemcitabine and cisplatin) (p<0.05 vs either single agent alone). U3-1287 (AMG 888) did not inhibit colony growth in the ZR- 75-30 model, but inhibits colony growth by 50%, 25%, 85% in the SkBr-3, MDA-MB453 and MDA-MB175VII breast cancer models, respectively, as a single agent (p<0.05) and up to 95% when combined with other HER inhibitors (p<0.05). 40%, 35% of the HER2+ and 10%, 35% of the HER2− human tumor samples had detectable pHER3 and pAKT, respectively. Conclusions: U3-1287 (AMG 888) inhibits proximal and distal HER3 oncogenic signaling in breast cell lines in vitro. Breast cancer cells are sensitive to U3-1287 (AMG 888) treatment as single agent and in combination with anti-HER agents. The preclinical data together with detectable levels of pHER3 in patient samples provide evidence for the potential clinical application of U3-1287 (AMG 888) in HER2+ and HER2− breast cancer.
Citation Information: Mol Cancer Ther 2009;8(12 Suppl):B161.
Collapse
|
41
|
Lum P, Ruixo JJP, Ogbagabriel S, Doshi S, Chen A, Yang BB, Hettman T, Radinsky R, Freeman D. Abstract B167: Identifying first in human (FIH) doses and schedule of U3-1287 (AMG 888), a fully human anti-HER3 mAb, based on preclinical pharmacokinetic (PK), pharmacodynamic (PD) and efficacy data. Mol Cancer Ther 2009. [DOI: 10.1158/1535-7163.targ-09-b167] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: HER3 is a member of the Human Epidermal Growth Factor Receptor (HER) family. Although HER3 lacks intrinsic kinase activity, it serves as a scaffold for PI3K/AKT signaling for the HER family via heterodimeric interactions. The goal of this study was to use preclinical modeling to predict a minimal effective dose regimen for objective response using preclinical PK and BxPC3 xenograft mice anti-tumor efficacy and PD data.
Materials and Methods: U3-1287 (AMG 888) concentration-time data obtained from mice (0.025 to 2.5 mg/mouse), rats (1 to 100 mg/kg) and monkeys (1 to 200 mg/kg) were combined and analyzed using a target-mediated drug disposition model. Animal PK parameters were scaled based on body weight to predict human PK characteristics. An Emax model was used to relate drug concentration and inhibition of pHER (measure by ELISA) in BxPC3 xenograft tumors. A PK/PD/efficacy model (based on Simeoni et al 2004) was used to analyze tumor growth data from mice bearing BxPC3 pancreatic xenografts (∼200 mm3) treated twice per week at 25, 100, 200, or 500 g for a 1 month. The model was validated with tumor growth data following additional doses of 400 g biweekly and 200 g biweekly, weekly and twice a week. The relationship between drug concentration, the inhibition of pHER3 in animals and interspecies PK scaling was used to select the minimal effective dose for the first in human study.
Results: U3-1287 (AMG 888) treatment of BxPC3 xenografts resulted in a statistically significant inhibition of tumor growth and pHER3 levels in a dose and schedule dependent manner (p<0.05). Treatment with U3-1287 (AMG 888) at 400 g/mouse biweekly and 200 g/mouse biweekly, weekly and twice a week resulted in a 50%, 33%, 74% and 70% inhibition of tumor growth (p<0.05), a 70%, 42%, 77% and 80% inhibition of pHER3 (measured by ELISA) versus the IgG control treated group, respectively. Serum concentrations of U3-1287 (AMG 888) at necropsy for the respective dose groups were (mean (SD)) of 2.07 (0.97), 0.45 (0.21), 3.08 (0.82) and 34.9 (9.1) g/mL, respectively. The estimated trough concentration needed to achieve 90% maximal pHER3 inhibition (IC90) was estimated to be ∼3 µg/mL. Based on interspecies scaling of PK parameters, a dose higher than 3 mg/kg given biweekly would achieve a steady-sate trough concentration that is above 3 µg/mL.
Conclusion: The anti-tumor efficacy in the BxPC3 pancreatic xenograft model was correlated with an increased serum concentration of U3-1287 (AMG 888) and a decrease in pHER3 levels, allowing for the development of a PK/PD/Efficacy relationship. This relationship combined with interspecies PK scaling was used to determine a dose and schedule for U3-1287 (AMG 888) to investigate in a FIH study.
Citation Information: Mol Cancer Ther 2009;8(12 Suppl):B167.
Collapse
|
42
|
Bush TL, Ziegler B, Chung G, McElroy PL, Kendall R, Radinsky R, Geuns-Meyer S, Payton M. Abstract C194: In vivo characterization of AMG 900, an orally active small molecule inhibitor of aurora kinases in phase 1 clinical trials. Mol Cancer Ther 2009. [DOI: 10.1158/1535-7163.targ-09-c194] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The aurora family of serine-threonine kinases (Aurora-A, -B, -C) regulate cell-cycle progression in mammalian cells. Aurora kinases A and B are essential for proper chromosome congression, segregation, and cytokinesis during mitosis, whereas aurora kinase C function appears restricted to male meiosis. Aurora kinase B is responsible for the direct phosphorylation of histone H3 on serine-10 (p-histone H3). Aurora kinase A and B expression is elevated in a variety of human cancers and is associated with advanced clinical staging and poor prognosis. The emergence of aurora kinases as key mitotic regulators and their potential role in tumorigenesis has focused substantial interest in developing selective small molecule inhibitors for the treatment of human cancers. AMG 900 is a novel ATP competitive small molecule inhibitor that is highly potent and selective for aurora kinases A, B, and C.
Objective: The aim of this study was to characterize the in vivo effects of AMG 900 by establishing a pharmacokinetic-pharmacodynamic relationship and profiling its antitumor activity across multiple human xenografts models using a variety of dosing schedules.
Results: In nude mice, oral administration of AMG 900 inhibited phosphorylation of histone H3 in tumors and bone marrow in a time- and dose-dependent manner. The degree of p-histone H3 suppression in cells correlated with plasma drug concentrations. The effect of AMG 900 was tested in a panel of human tumor xenograft models. Oral administration of AMG 900 at 15 mg/kg BID for two consecutive days per week or 3 mg/kg BID every day inhibited tumor growth (50–97% inhibition; p ≤ 0.0044) in all nine of the xenograft models tested compared with the vehicle control group. Importantly, three of these xenograft models are resistant to paclitaxel, docetaxel, and doxorubicin. Mice treated with efficacious doses of AMG 900 showed a transient loss of body weight (0–10%) and bone marrow cellularity, consistent with its on-mechanism effects on normal proliferating cells. Since aurora kinase inhibitors are known to cause neutropenia, studies were performed to investigate the effects of prophylactic treatment of PEGylated-G-CSF (SD/02). In mice, administration of SD/02 shortened the duration of AMG 900-induced neutropenia.
Conclusion: Based on these preclinical activities, AMG 900 has the potential to treat advanced cancers, including tumors resistant to standard-of-care chemotherapeutic agents such as paclitaxel and docetaxel. AMG 900 is currently undergoing phase 1 clinical evaluation in patients with advanced solid tumors.
Citation Information: Mol Cancer Ther 2009;8(12 Suppl):C194.
Collapse
|
43
|
Freeman DJ, Bush T, Ogbagabriel S, Belmontes B, Juan T, Plewa C, Van G, Johnson C, Radinsky R. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor. Mol Cancer Ther 2009; 8:1536-46. [DOI: 10.1158/1535-7163.mct-08-0978] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
44
|
Coxon A, Rex K, Meyer S, Sun J, Sun J, Chen Q, Radinsky R, Kendall R, Burgess TL. Soluble c-Met receptors inhibit phosphorylation of c-Met and growth of hepatocyte growth factor: c-Met–dependent tumors in animal models. Mol Cancer Ther 2009; 8:1119-25. [DOI: 10.1158/1535-7163.mct-08-1032] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
45
|
Coxon A, Bush T, Saffran D, Kaufman S, Belmontes B, Rex K, Hughes P, Caenepeel S, Rottman JB, Tasker A, Patel V, Kendall R, Radinsky R, Polverino A. Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors. Clin Cancer Res 2009; 15:110-8. [PMID: 19118038 DOI: 10.1158/1078-0432.ccr-08-1155] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
PURPOSE Angiogenesis plays a critical role in breast cancer development and progression. Vascular endothelial growth factor (VEGF) is a potent angiogenic factor that regulates endothelial cell proliferation and survival. We investigated the effects of motesanib, a novel, oral inhibitor of VEGF receptors 1, 2, and 3; platelet-derived growth factor receptor; and Kit receptor, on the growth of xenografts representing various human breast cancer subtypes. EXPERIMENTAL DESIGN Athymic nude mice were implanted with MCF-7 (luminal) or MDA-MB-231 (mesenchymal) tumor fragments or Cal-51 (mixed/progenitor) tumor cells. Once tumors were established, animals were randomized to receive increasing doses of motesanib alone or motesanib plus cytotoxic chemotherapy (docetaxel, doxorubicin, or tamoxifen). RESULTS Across all three xenograft models, motesanib treatment resulted in significant dose-dependent reductions in tumor growth, compared with vehicle-treated controls, and in marked reductions in viable tumor fraction and blood vessel density. No significant effect on body weight was observed with compound treatment compared with control-treated animals. Motesanib did not affect the proliferation of tumor cells in vitro. There was a significantly greater reduction in xenograft tumor growth when motesanib was combined with docetaxel (MDA-MB-231 tumors) or with the estrogen receptor modulator tamoxifen (MCF-7 tumors), compared with either treatment alone, but not when combined with doxorubicin (Cal-51 tumors). CONCLUSIONS Treatment with motesanib alone or in combination with chemotherapy inhibits tumor growth in vivo in various models of human breast cancer. These data suggest that motesanib may have broad utility in the treatment of human breast cancer.
Collapse
Affiliation(s)
- Angela Coxon
- Department of Oncology Research, Amgen, Inc., Thousand Oaks, California, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Beltran PJ, Mitchell P, Chung YA, Cajulis E, Lu J, Belmontes B, Ho J, Tsai MM, Zhu M, Vonderfecht S, Baserga R, Kendall R, Radinsky R, Calzone FJ. AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Mol Cancer Ther 2009; 8:1095-105. [PMID: 19366899 DOI: 10.1158/1535-7163.mct-08-1171] [Citation(s) in RCA: 113] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Pancreatic carcinoma is a leading cause of cancer deaths, and recent clinical trials of a number of oncology therapeutics have not substantially improved clinical outcomes. We have evaluated the therapeutic potential of AMG 479, a fully human monoclonal antibody against insulin-like growth factor (IGF) type I receptor (IGF-IR), in two IGF-IR-expressing pancreatic carcinoma cell lines, BxPC-3 and MiaPaCa2, which also differentially express insulin receptor (INSR). AMG 479 bound to IGF-IR (K(D) 0.33 nmol/L) and blocked IGF-I and IGF-II binding (IC(50) < 0.6 nmol/L) without cross-reacting to INSR. AMG 479 completely inhibited ligand-induced (IGF-I, IGF-II, and insulin) activation of IGF-IR homodimers and IGF-IR/INSR hybrids (but not INSR homodimers) leading to reduced cellular viability in serum-deprived cultures. AMG 479 inhibited >80% of basal IGF-IR activity in BxPC-3 and MiaPaCa2 xenografts and prevented IGF-IR and IGF-IR/INSR hybrid activation following challenge with supraphysiologic concentrations of IGF-I. As a single agent, AMG 479 inhibited (∼ 80%) the growth of pancreatic carcinoma xenografts, and long-term treatment was associated with reduced IGF-IR signaling activity and expression. Efficacy seemed to be the result of two distinct biological effects: proapoptotic in BxPC-3 and antimitogenic in MiaPaCa2. The combination of AMG 479 with gemcitabine resulted in additive inhibitory activity both in vitro and in vivo. These results indicate that AMG 479 is a clinical candidate, both as a single agent and in combination with gemcitabine, for the treatment of patients with pancreatic carcinoma
Collapse
Affiliation(s)
- Pedro J Beltran
- Oncology Research Therapeutic Area, Amgen Inc, One Amgen Center Drive, Thousand Oaks, California 91320, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Kruser TJ, Armstrong EA, Ghia AJ, Huang S, Wheeler DL, Radinsky R, Freeman DJ, Harari PM. Augmentation of radiation response by panitumumab in models of upper aerodigestive tract cancer. Int J Radiat Oncol Biol Phys 2008; 72:534-42. [PMID: 18793955 DOI: 10.1016/j.ijrobp.2008.06.1490] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2008] [Revised: 05/26/2008] [Accepted: 06/01/2008] [Indexed: 12/25/2022]
Abstract
PURPOSE To examine the interaction between panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, and radiation in head-and-neck squamous cell carcinoma and non-small-cell lung cancer cell lines and xenografts. METHODS AND MATERIALS The head-and-neck squamous cell carcinoma lines UM-SCC1 and SCC-1483, as well as the non-small-cell lung cancer line H226, were studied. Tumor xenografts in athymic nude mice were used to assess the in vivo activity of panitumumab alone and combined with radiation. In vitro assays were performed to assess the effect of panitumumab on radiation-induced cell signaling, apoptosis, and DNA damage. RESULTS Panitumumab increased the radiosensitivity as measured by the clonogenic survival assay. Radiation-induced epidermal growth factor receptor phosphorylation and downstream signaling through mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription 3 (STAT3) was inhibited by panitumumab. Panitumumab augmented radiation-induced DNA damage by 1.2-1.6-fold in each of the cell lines studied as assessed by residual gamma-H(2)AX foci after radiation. Radiation-induced apoptosis was increased 1.4-1.9-fold by panitumumab, as evidenced by Annexin V-fluorescein isothiocyanate staining and flow cytometry. In vivo, the combination therapy of panitumumab and radiation was superior to panitumumab or radiation alone in the H226 xenografts (p = 0.01) and showed a similar trend in the SCC-1483 xenografts (p = 0.08). In vivo, immunohistochemistry demonstrated the ability of panitumumab to augment the antiproliferative and antiangiogenic effects of radiation. CONCLUSION These studies have identified a favorable interaction in the combination of radiation and panitumumab in upper aerodigestive tract tumor models, both in vitro and in vivo. These data suggest that clinical investigations examining the combination of radiation and panitumumab in the treatment of epithelial tumors warrant additional pursuit.
Collapse
Affiliation(s)
- Tim J Kruser
- Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
| | | | | | | | | | | | | | | |
Collapse
|
48
|
Brake R, Starnes C, Lu J, Chen D, Yang S, Radinsky R, Borges L. Effects of palifermin on antitumor activity of chemotherapeutic and biological agents in human head and neck and colorectal carcinoma xenograft models. Mol Cancer Res 2008; 6:1337-46. [PMID: 18708365 DOI: 10.1158/1541-7786.mcr-07-2131] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Damage to the gastrointestinal mucosa is a common dose-limiting toxicity of several anticancer therapies. Until recently, adequate control of oral mucositis was considered a significant unmet medical need, with most available treatments providing only palliative benefits without protecting the gastrointestinal epithelium from the damaging effects of cancer therapy. In 2005, palifermin [recombinant human keratinocyte growth factor (KGF)] was approved to decrease the incidence and duration of severe oral mucositis in patients with hematologic malignancies receiving myelotoxic therapy requiring hematopoietic stem cell support. Current trials are investigating the use of palifermin in solid tumor settings. The objective of this study was to determine whether combining palifermin with different chemotherapeutic or biological agents affected the antitumor activity of these agents in human head and neck (FaDu) and colorectal (HT29) carcinoma xenograft models. Nude CD1 mice were injected with 1 x 10(7) of either FaDu or HT29 cells, which express both KGF and epithelial growth factor receptors. Animals were treated with palifermin in various combinations with chemotherapeutic (5-fluorouracil and cisplatin) and/or biological (bevacizumab, cetuximab, and panitumumab) agents. Palifermin alone had no effect on either FaDu or HT29 tumor growth. Palifermin did not affect the therapeutic efficacy of 5-fluorouracil, cisplatin, cetuximab, bevacizumab, or panitumumab in any of the two- or three-way drug combinations tested in either model. The results of this study showed that palifermin did not promote the growth of two carcinoma cell lines that express functional KGF receptors and did not protect these tumor cells from the antitumor effects of several chemotherapeutic and biological agents.
Collapse
MESH Headings
- Animals
- Antibodies, Monoclonal/pharmacology
- Antibodies, Monoclonal/therapeutic use
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents/therapeutic use
- Bevacizumab
- Cell Line, Tumor
- Cell Proliferation/drug effects
- Cetuximab
- Cisplatin/pharmacology
- Cisplatin/therapeutic use
- Colorectal Neoplasms/drug therapy
- Colorectal Neoplasms/genetics
- Colorectal Neoplasms/pathology
- Drug Therapy, Combination
- ErbB Receptors/genetics
- ErbB Receptors/metabolism
- Female
- Fibroblast Growth Factor 7/pharmacology
- Fibroblast Growth Factor 7/therapeutic use
- Fluorouracil/pharmacology
- Fluorouracil/therapeutic use
- Gene Expression Regulation, Neoplastic/drug effects
- Head and Neck Neoplasms/drug therapy
- Head and Neck Neoplasms/genetics
- Head and Neck Neoplasms/pathology
- Humans
- Mice
- Receptor, Fibroblast Growth Factor, Type 2/genetics
- Receptor, Fibroblast Growth Factor, Type 2/metabolism
- Xenograft Model Antitumor Assays
Collapse
Affiliation(s)
- Rachael Brake
- Hematology and Oncology Research, Amgen, Inc., 1201 Amgen Court West, Seattle, WA 98119, USA
| | | | | | | | | | | | | |
Collapse
|
49
|
Freeman DJ, Juan T, Reiner M, Hecht JR, Meropol NJ, Berlin J, Mitchell E, Sarosi I, Radinsky R, Amado RG. Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer 2008; 7:184-90. [PMID: 18621636 DOI: 10.3816/ccc.2008.n.024] [Citation(s) in RCA: 132] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
BACKGROUND Identifying predictive biomarkers is important to optimally treat patients. This analysis evaluated the association of K-ras, BRAF, and PIK3CA gene mutations with tumor resistance to panitumumab alone. PATIENTS AND METHODS From 3 phase II panitumumab metastatic colorectal cancer (mCRC) studies, 62 of 533 patient samples were available. Mutations were identified from genomic DNA by sequencing. RESULTS Of the 62 samples, 24 (38.7%) harbored a K-ras mutation, and 38 (61.3%) were wild type. In the wild-type K-ras group, 11% of patients had a partial response (PR), 53% had stable disease (SD), and 37% had progressive disease (PD). In the mutant K-ras group, 21% of patients had SD, and 79% of patients had PD; there were no responses. The absence of a K-ras mutation was associated with response to panitumumab (PR vs. SD vs. PD; P = .0028). The hazard ratio for wild-type versus mutant K-ras was 0.4 (95% CI, 0.2-0.7) for progression-free survival and 0.5 (95% CI, 0.3-0.9) for overall survival. Four patients had a V600E BRAF mutation, and 2 patients had a PIK3CA mutation. CONCLUSION These data suggest that patients with mCRC with activating K-ras mutations are less likely to respond to panitumumab alone. The small sample size limits us from defining a predictive role of PIK3CA and BRAF mutations for panitumumab treatment.
Collapse
Affiliation(s)
- Daniel J Freeman
- Department of Oncology Research, Amgen Inc, Thousand Oaks, CA 91320, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Beltran PJ, Mitchell P, Moody G, Chung Y, Cajulis E, Belmontes B, Radinsky R, Calzone F. Effect of AMG 479 on anti-tumor effects of gemcitabine and erlotinib against pancreatic carcinoma xenograft models. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.4617] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|